An investigation of the relationship between bipolar disorder and cannabis use by Barrowclough, Christine et al.
  
 
An investigation of the relationship 
between Bipolar Disorder and  
Cannabis use 
 
 
 
A thesis submitted to the University of Manchester for the degree of Doctor of 
Clinical Psychology in the Faculty of Medical and Human Sciences 
 
 
ELIZABETH TYLER 
 
School of Psychological Sciences 
Division of Clinical Psychology 
 
 
 
 
 
2 
 
LIST OF CONTENTS 
 
ABSTRACT FOR THESIS……………………………………………………………………………………….…………...9 
DECLARATION…………………………………………………………………………………………………….………….10 
COPYRIGHT STATEMENT………………………………………………………………………………………………..11 
ACKNOWLEDGEMENTS………………………………………………………………………………………………….12 
 
PAPER 1 - The co-occurrence of bipolar disorder and cannabis use: A review paper 
 
TITLE PAGE………………………………………………………………………………………………………………….….………13 
PREFACE……………………………………………………………………………………………………………………….……… 14 
ABSTRACT…………………………………………………………………………………………………………………….………..15 
IINTRODUCTION………………………………………………………………………………………………………….…………16 
METHOD……………………………………………………………………………………..…………………………….…………..17 
Literature search……………………………………………………..……………………………………….…….…17 
Study selection………….………………………………………………………………………………….…..………17 
Study samples / inclusion criteria……………………………………………..……………….………………17 
RESULTS……………………………………………………………….………………………………………………………….…….18 
Hypothesis 1……………………………………………………………………..………….…………………………..22 
Hypothesis 2………………………………………………………………………..…….……………………………..26 
Hypothesis 3…………………………..………………………….……………..………………………………………29 
Hypothesis 4………………………………..…………………………………………………………………………….31 
SUMMARY……………………………………………………………………………………………………………………….…….33 
REFERENCES……………………………………………………………………………………………………………………..36 
 
 
PAPER 2 - The relationship between bipolar disorder and cannabis use in daily life: An 
experience sampling study 
 
TITLE PAGE…………………………………………………………….…………………………………………………………….…43 
3 
 
PREFACE…………………………………………………………………………………………………………………………………44 
ABSTRACT………………………………………………………………………………………………………………………………45 
INTRODUCTION………………………………………………………………………………………………………………………46 
METHOD……………………………………………………………………………………..………………………………….………48 
Participants………………………………………………………………………..………………………………………48 
Experience sampling method………………………..…………………………………………………….….…49 
Procedure……………………………………………………………………..………………………….………….……49 
MEASURES…………………………………………………………………………………..………………………….………..……50 
The experience sampling diary…………………………………………………….…………...…50 
Mood items…………………………………………………………..………………….….…………….…50 
 
BD symptoms…………………………………………………………..……………………..….…………50 
BAS sensitivity ………………………………………………………..…………………….…….…………50 
Substance use………………………………………………………..…………………….………….……51 
Questionnaire……………………………………………………………………..…………………….………………51 
BIS/BAS scale…………………………………………………………..…………………….………………51 
STATISTICAL ANALYSIS STRATEGY……………………………………………………………….……….…………….52 
Preliminary analyses……………………………………………………………………..……………………………53 
Self medication effects ……………………………………………………………………..……………………….53 
Cannabis effects on mood and BD symptoms……………………………………………………54 
 
BAS sensitivity effects on cannabis use, mood and BD symptoms………………….………..…54 
Temporal analyses of cannabis use……………………………………………………………….….…………54 
Investigating the association between BAS total score and mood / symptoms 
/cannabis……………………………………………………………………………………………………….……………55 
RESULTS……………………………………………………………………..……………………………………………………………55 
Participants…………………………………………………………………..…..…………….…………….……55 
Substance use………………………………………………………………….…..…………………………….….……56 
 BIS/BAS Scale……………………………………………………………………..……………………………………..…57 
 Preliminary analyses……………………………………………………………………..………………..……..……57 
Self medication effects……………………………………………………………………..…………………………59 
4 
 
Cannabis effects on mood and BD symptoms………………………………………………………………59 
BAS sensitivity effects on cannabis use, mood and BD symptoms…………………….………….60 
Temporal dynamics of cannabis use…………………………………………………….…………..………….60 
Investigating the association between BAS total score and mood / symptoms  
/ cannabis use……………………………………………………………………..………………………………………61 
DISCUSSION……………………………………………………………………………………..………………………………………62 
 Cannabis effects……………………………………………………………………..……………………………………62 
 Effects of mood / BD symptoms on cannabis use (Self medication effects)…………………63 
Effects of the BAS……………………………………………………………………..……………….…………………64 
LIMITATIONS……………………………………………………………………..……………………………….……………………65 
CLINICAL IMPLICATIONS……………………………………………………………………..…………………..………………66 
FUTURE RESEARCH………………………………………………………………………………………………………………67 
REFERENCES…………………………………….…………………………………………………………….……………………68 
 
PAPER 3 – A critical reflection of the research process 
TITLE PAGE………………………………………………………………………………………………………………………….……75 
OVERVIEW………………………………………………………………………………………………………………………….……77 
THE LITERATURE REVIEW………………………………………………………………………..………………………….……77 
THE EMPIRICAL PAPER……………………………………………………………………………………………….……….78 
THE STUDY CONTEXT………………………………………………………………..………………………………..………79 
METHODOLOGICAL CONSIDERATIONS…………………………………………………………………………………79 
Experience sampling methodology……………………………………….……………………….……………79 
Limitations of ESM…………………………………………………………………….………………….………..……80 
Developing items for the ESM diary………………………………………………………….….……..………81 
Service user involvement with the ESM diary………………………………………………………………82 
BIS/BAS scale (Carver and White, 1994) ………………………….…………………………….………….…83 
Recruitment……………………………………………………………….……………………………….…………….…83 
Cannabis use………………………………..………………………………………………….…………….……………85 
5 
 
Assessment of cannabis use/ other substances…………………………………………..….………….86 
The participant sample………………………………………………………………….……………….…………87 
Statistical analyses……………………………………………………………………………………….……………87 
Participant feedback on the study……………………………………………………………….……………88 
ETHICAL CONSIDERATIONS………………………………………………….…………………….…………….……………89 
Consent…………………………..…………………………………………………………….…………….……………89 
Confidentiality…………………………………………………………………………………….……….……………89 
STUDY IMPLICATIONS…………………….……………………………………………………………….……….……………90 
Theoretical and future implications…………………………………………………………….……………90 
Effects of Cannabis………………………………………………………………………….…………….90 
Self-medication………..………………………………………………………………….……………….92 
BAS theory……………………………..……………………………………………………….…………….93 
Implication of the study for clinical practice………………………………………………………….95 
REFERENCES………………………………………………………………………………………………………..…………….96 
APPENDICES…………………………………………………………………………………………………………………….103 
 
 
 
 
 
 
 
 
 
 
6 
 
LIST OF TABLES  
 
PAPER 1 - The co-occurrence of bipolar disorder and cannabis use: A review paper 
Table 1……………………………………………………………………………………………………………………………………19 
 
PAPER 2 - The relationship between bipolar disorder and cannabis use in daily life:  An 
experience sampling study 
Table 1……………………………………………………………………………………………………………………………………56 
Table 2……………………………………………………………………………………………………………………………………57 
Table 3……………………………………………………………………………………………………………………………………59 
Table 4……………………………………………………………………………………………………………………………………59 
Table 5……………………………………………………………………………………………………………………………………60 
Table 6……………………………………………………………………………………………………………………………………61 
Table 7……………………………………………………………………………………………………………………………………61 
 
 
 
 
 
 
 
 
 
 
7 
 
LIST OF FIGURES 
 
PAPER 2 - The relationship between bipolar disorder and cannabis use in daily life: An 
experience sampling study 
Figure 1…………………………………………………………………………………………………………………………………53 
Figure2……………………………………………………………………………………………………………………………….…58 
 
PAPER 3 - A critical reflection of the research process 
Figure 1……………………………………………………………………………………………………………………………….…84 
Figure2………………………………………………………………………………………………………………………………….93 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8 
 
WORD COUNT 
 
Thesis Section Text Abstracts, tables, 
figures, references  
Appendices Total 
Thesis abstract         434 ---- --- 434 
Paper one 
(Literature 
Review) 
6,230 3,171 --- 9,401 
Paper two 
(Empirical Paper) 
5,879 2,248 --- 8,127 
Paper Three              
(Critical review ) 
6,371 1,895 4,838 13,104 
Total 18,914       7,314          4,838 31,066 
 
 
 
 
 
 
 
 
 
 
9 
 
 
ABSTRACT 
Substance abuse is very common in Bipolar Disorder (BD) and can lead an individual 
having an increased range of difficulties. Studies have indicated that cannabis is used 
very frequently, but most research into substance use and BD has focused on either 
alcohol use or substance use disorders generally.  The relationship between BD and 
cannabis use specifically has received far less attention. This thesis specifically explored 
the co-occurring relationship between BD and cannabis use.  
In the first section the author examines and critically evaluates studies that have 
reported on the relationship between BD and cannabis use. The initial phase included a 
literature search of the area and the identification of relevant papers. A total of 13 
research studies were identified and included in the final review.  The studies varied 
considerably in terms of their research questions, design and methodological quality. 
The findings from the studies were synthesised in relation to a number of existing 
hypotheses for why BD and substance use in general co-occur. On the whole, the 13 
studies contributed sufficient evidence both for and against the existing hypotheses. 
The findings suggest that there are a number of factors that contribute towards the high 
co-occurrence of BD and cannabis use (e.g. the use of cannabis to self-medicate 
symptoms). 
The second section was designed to investigate a number of the factors derived from 
the literature which might explain the high co-occurrence of BD and cannabis use. The 
Experience Sampling Methodology (ESM) was utilised to provide a close investigation of 
a number of factors over the course of daily life. Twenty-three participants with BD type 
I and type II completed diary entries for 6 days using ESM. The procedure allowed a 
close investigation into the associations between cannabis, mood, BD symptoms and 
Behavioural Activation System (BAS) sensitivity. Self-reported BAS was also measured to 
indicate the extent to which this predicted changes in mood, BD symptoms and 
cannabis use. The findings indicate that cannabis use is associated with a number of 
psychological effects, although no evidence for the self- medication of mood and BD 
symptoms was revealed in the daily life of the participants. An association between BAS 
sensitivity and positive affect and manic symptoms was revealed and this is consistent 
with the findings in current literature.  
The final section provides a critical reflection of the research process. This includes a 
rationale for the development of the literature review and the main research paper. 
This is followed by a description of the study context and then a reflection on the 
methodological and ethical issues which were faced. Finally it discusses theoretical, 
clinical and future implications for research in this area.  
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ABSTRACT 
 
Objectives: Cannabis use is very common in Bipolar Disorder (BD). However, most research into 
substance use and BD has focused on either alcohol use or substance use in general. The 
relationship between cannabis use and BD has received far less attention.  
Method: In this review the author examines and critically evaluates studies which report on the 
specific relationship between BD and cannabis. These findings are synthesised in relation to a 
number of existing hypotheses for why BD and substance use in general co-occur.  
Results: From a systematic search of the literature 13 relevant studies were identified and were 
included in the review. These studies varied considerably in terms of the research questions and 
design (e.g. longitudinal, cross-sectional, experimental, and qualitative), as well as the 
methodological quality.  
Conclusions: Taken as a whole, the studies contribute sufficient evidence with which to re-
consider the existing hypotheses in the context of cannabis use and BD.  The findings suggest 
that there appear to be a number of factors that contribute to the high occurrence of BD and 
cannabis use, including the use of cannabis to self-medicate symptoms of BD. The review 
highlighted a number of areas which warrant further attention and these are discussed further 
in the paper.   
 
Keywords: bipolar disorder, mania, cannabis use, substance use, self-medication 
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INTRODUCTION 
Approximately 50-60% of individuals with Bipolar Disorder (BD) have a lifetime history of 
substance use disorder (1, 2). Furthermore, studies report that rates of substance use are 
elevated in people with BD compared to the general population (1, 3). Co-occurring BD and 
substance use often show a more severe course of illness including poor insight and denial (4); 
increased suicide attempts (5) and higher levels of symptom severity (6). 
A review paper investigating the co-occurrence of BD and substance use disorders (7) examined 
4 possible hypotheses for the high levels of co-morbidity reported.  [1] Substance abuse is a 
symptom of BD due to the nature of the condition, which may lead to ‘risky’ behaviour and poor 
judgement (8, 9).  [2] Substance abuse is developed as a way of coping with BD, ‘the self 
medication hypothesis’ (10, 11, 12). [3] Substance abuse causes BD by repeated use, inducing 
changes in the brain, subsequently altering affect (13, 14). [4] Substance use disorders and BD 
share common risk factors such as genetic vulnerabilities (9), elevated levels of impulsivity (15) 
or sensation seeking (12).  However the authors conclude that none of the 4 hypotheses have 
clear support for explaining all cases of co-occurrence and suggest all 4 mechanisms may play a 
role in the excessive substance abuse observed in individuals with BD. 
Overall, research has revealed that cannabis is the most frequently used drug in individuals with 
BD (2, 16, 17); this pattern mirrors rates in the general population (18).   
The major psychoactive component in cannabis is ∆9-tetrahydrocannabinol (THC). THC 
replicates the actions of natural cannabinoids produced in the body and binds itself to 
cannabinoid receptors CB1 and CB2. These receptors are found within several regions of the 
brain, including the frontal cortex, striatum and hippocampus (19, 20, 21). Neuro-anatomical 
findings suggest CB1 modulates and interacts with the function of dopamine (22). Whilst 
evidence suggests this interaction modulates a variety of areas, including affect, appetite, 
learning and memory (23, 24), little is understood regarding the underlying molecular 
mechanisms. Further understanding of the interaction and the mechanisms involved may have 
important implications for individuals with BD who use cannabis, since the disorder is 
characterised by difficulties with affect regulation.    
Estimates of current cannabis use for individuals with BD range from 8% to 22% and for lifetime 
use the estimates range from 30% to 64% (25). In a number of studies, particularly those with a 
younger participant sample, cannabis use equalled or exceeded alcohol use disorders (1, 17, 
17 
 
26). However, most research into substance use and BD has focused on either alcohol use or 
substance use disorders generally and the relationship between BD and cannabis use specifically 
has received far less attention.  
Whilst Strakowski and DelBello’s (7) paper provided a comprehensive review of studies 
investigating the co-occurrence of BD and substance use disorders generally, to the author’s 
knowledge there are no published reviews exploring the specific relationship between BD and 
cannabis use. The present paper focuses exclusively on BD and cannabis use and aims to 
evaluate the 4 hypotheses of Strakowski and DelBello’s (7) through examining and critically 
evaluating studies which report on the relationship between BD and the use of this specific 
drug.  
 
METHOD 
Literature search 
The following databases were searched from inception to January 2011:  EMBASE, MEDLINE, 
Psych info and the Web of Science. Search terms included ‘bipolar’ OR ‘manic depression’ OR 
‘mania’ AND ‘cannabis/ marijuana use’ OR ‘cannabis/marijuana abuse’ OR ‘cannabis/marijuana 
misuse’. The reference lists of abstracts were also searched.  
Study selection 
All titles and abstracts were examined and full text papers of potentially relevant studies 
obtained. All papers were read to determine whether they met the following inclusion criteria 
for the review.  
Study samples / inclusion criteria 
All studies that investigated individuals with BD and co-occurring cannabis use were included. 
These examined individuals with a diagnosis of BD or sub-threshold BD symptoms at baseline or 
who were at risk of developing BD or BD sub-threshold symptoms post-baseline.  
Studies were also included which examined individuals with a different mental health diagnosis 
(e.g. anxiety disorders).  However for the purpose of this review the participant sample had to 
include 50% or more people with BD or BD sub-threshold symptoms.  
18 
 
The following diagnostic groups for BD were included in the review: BD type I or II, rapid cycling 
BD, BD not otherwise specified (NOS) and also studies which included sub threshold BD 
conditions that required either a reduced duration or number of symptoms, as verified by the 
Diagnostic and Statistical Manual of Mental Disorders -revised 4th ed. (DSM-IV: 27) criteria. All 
levels of cannabis use were included in the review.   
Studies in languages other than English were not considered for inclusion.  
RESULTS 
The original search yielded 81 papers of which 68 were excluded for not meeting the inclusion 
criteria outlined above. Reasons for exclusion were as follows:  
§ Investigations of cannabis use and psychosis  
§ Investigations of cannabis use and other mental health difficulties (did not include 50% 
or more individuals with BD)  
§ Investigations of substance use in general and BD  
§ Review papers of cannabis and mental health difficulties in general  
§ Review papers of substance use and BD 
§ Not in the English language 
 
A total of 13 papers therefore were included in the final review, none of which were included in 
Strakowski and DelBello’s (7) review paper. These studies employed a range of designs, 
including case, case-control, cohort and cross-sectional. Further details of these studies can be 
found in table 1.  
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Hypothesis 1:  Substance abuse occurs as a symptom of BD 
BD is characterised by extreme contrasts in mood, recurrent episodes of acute mania, depression 
and mixed state emotions. Signs of depression include feelings of guilt and worthlessness, insomnia 
or hypersomnia, impaired concentration and thoughts of death and suicide. Mania, in contrast is 
associated with increased self-esteem, pressured speech, a decreased need for sleep, flight of ideas, 
distractibility and an increase in risk- taking behaviours. These characteristics, particularly the 
increase in risk taking behaviours, have led investigators to hypothesise that the high levels of 
substance abuse observed in people with BD may be due to the nature of the condition (8, 9).  
Strakowski and DelBello (7) hypothesise that substance abuse may be a symptom of BD and suggest 
that this leads to two predictions: 
[1] substance abuse begins after the onset of BD 
[2] substance abuse is state dependent, therefore the amount of substance use changes 
depending on the individual’s current mood state  
The community based Zurich cohort study (28) provides data to test the first prediction of 
Strakowski and DelBello (7) that cannabis use begins after the onset of BD. Merikangas et al (28) 
aimed to examine the degree to which BD spectrum conditions increased the risk for various 
substance use disorders. Previous epidemiological research investigating the co-morbidity of mood 
disorders and substance use often relied on either cross-sectional design, making it difficult to 
ascertain causal inferences or retrospective estimates of disorder onset, which may be open to bias. 
In response to the methodological issues that can arise from using such data, a prospective study 
design was utilised.  
Over a 20-year period, young adults (age 19-20) were interviewed at six time points in their home 
environment. Substance use, mood disorders and sub-threshold symptoms of these disorders, 
based on DSM-IV (27) criteria were assessed at each interview. Participants meeting criteria for 
cannabis abuse and dependence at baseline were excluded from analyses. The development of 
later cannabis abuse/ dependence (OR, 4.82; 95% CI, 2.0-11.06) was significantly predicted by the 
presence of sub-threshold manic symptoms at baseline. However the study did not control for the 
influence of factors such as gender and personality traits (for example impulsivity). An adjustment 
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for such factors may affect the associations reported as trait impulsivity has been identified as a 
shared risk factor for the development of BD and substance use disorders (15).  
As the authors highlighted, the 20-year attrition rate of 38% in the Zurich study (28) may indicate 
that the sample is self-selected and therefore unrepresentative, which could lead to difficulties 
generalising results from this study to other populations. Additionally, whilst the cohort was 
assessed until their 40th year, in fact the last assessment of mood was made in the participants’ 35th 
year due to the prospective nature of the analyses. It follows that their findings may not generalise 
to older populations. 
The study outlined above provides some support for the prediction that substance abuse begins 
after the onset of BD.  However this is limited to manic symptoms (below current diagnostic 
thresholds) rather than a clinical diagnosis of BD. In addition, analyses were limited to investigating 
the risk posed by BD to the later development of cannabis use disorders. Merikangas et al (28) 
recognise the need to take into account the bidirectional associations that may be present in the 
data but were not investigated in this study.   
In contrast, a longitudinal population based study (29), utilizing the Composite International 
Diagnostic Interview (CIDI: 30),  found that over a 3-year follow up period, manic symptoms at 
baseline did not predict the onset of cannabis use during follow up  (OR = 2.70, 95% CI: 1.54-4.75). 
Furthermore they found that cannabis use at baseline in-fact increased the risk for manic symptoms 
during follow up (OR = 2.70, 95% CI: 1.54-4.75).  Participants did not meet criteria for a mood 
disorder at baseline. 
Similarly, two additional studies (31, 32) used the CIDI (30) to assess whether lifetime cannabis use 
predicted increased risk for first incidence of mood disorders over specific time periods; likewise 
participants did not meet criteria for a mood disorder at baseline. 
Using a longitudinal study design with an 8 year follow up, Tijssen et al (32) investigated risk factors 
for predicting onset and persistence of sub-threshold BD symptoms in adolescents. Participants (n = 
543) did not have a history of manic symptoms at baseline. They found onset of manic symptoms 
was associated with lifetime cannabis use (defined as minimum usage of five times at baseline; OR 
4.26; 95% CI 1.42-12.76, P = 0.010). Both Tijssen et al (32) and Henquet et al (29) examined sub-
threshold manic symptoms in the general population. Therefore there may be difficulties with 
generalising the reported association to people with a clinical diagnosis of BD.  
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Van Laar et al (31) interviewed participants (n= 3881) over a three year period and found any use of 
cannabis at baseline predicted first incidence of BD (OR = 4.98%, 95% CI: 1.80-13.81), based on 
DSM-III-R (33) criteria. The association remained significant, even when they adjusted for strong 
confounders such as alcohol and other substance use disorders, lifetime psychotic symptoms and 
lifetime anxiety symptoms.  
Taken together, the studies reviewed so far provide a complex picture of co-occurring BD and 
cannabis use. It appears to be the case that cannabis use can occur before or after the development 
of BD. Whilst one study (28) indicates that the BD symptoms predict later cannabis use, one study 
fails to support this direction of effects (29) and several other studies indicate a the reverse 
causation; with cannabis use at baseline predicting the later development of BD symptoms (29, 
31,32).  
Data from these studies (29, 31, 32) challenge the first prediction of Strakowski and DelBello (7) 
that cannabis use begins following the onset of BD, since a high proportion of participants had 
begun to use cannabis prior to the onset of BD symptoms.  
The second prediction from Strakowski and DelBello’s (7) hypothesis (that substance use may be a 
symptom of BD) is that substance abuse is state dependent, therefore the amount of substance use 
changes depending on an individual’s current mood state.  
Unfortunately, none of the studies in the current review investigate the actual amount of cannabis 
used over the course of BD. However, there is data available which investigates periods of cannabis 
use versus non-use. Strakowski et al (34) studied the sequence of onset of BD and cannabis use 
disorder, based on previous studies that focused on co-occurring alcohol use and BD (8, 26). They 
investigated the course of BD and cannabis use disorders after a first psychiatric hospitalisation of 
mania by comparing patients whose BD onset preceded the development of cannabis use disorder 
and patients whose cannabis use began before onset of BD. The 2 groups demonstrated significant 
differences in their improvement, the cannabis first group exhibited better recovery. However 
when adjusted for potential mediator variables (i.e. age, gender, education, rates of other 
substance use disorders and age of onset of BD) these results did not remain significant. More than 
70% of the patients using cannabis prior to hospitalisation did not resume use for at least 8 weeks 
following discharge.  
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This study provides some support for the second prediction; that substance use changes depending 
on the person’s mood state. However there may have been other factors involved which led to a 
change in their typical cannabis use, such as access to money or loss of contacts to purchase 
cannabis following their discharge from hospital.  
Another prospective study (35) followed 166 people with first episode BD I over the course of 4.7 
years, using the Longitudinal Interval Follow up Evaluation (LIFE), based on DSM-IV (27) criteria. 
Participants were rated for the presence or absence of affective morbidity or substance use within 
three-month (quarterly) intervals.  Findings revealed manic or hypomanic morbidity was associated 
with cannabis use during the same quarter (RC = 0.116; 95% CI = 0.053-0.178; z-score = 3.63, p < 
0.001) and the preceding quarter (RC = 0.111; 95% CI = 0.054-0.168; z-score = 3.80, p< 0.001) but 
not in the following quarter. Cannabis use was not related to changes in depressive symptoms. For 
analysis manic and hypomanic morbidity was dichotomised as either present or absent, regardless 
of severity and included sub-syndromal mania or hypomania. This approach may have reduced the 
accuracy of the reported associations.  
Whilst a number of methodological issues have been raised in the 2 studies above (34, 35) their 
results nonetheless provide some evidence to support the second prediction.  Their findings are 
consistent with the suggestion that there is a selective association of particular substances 
depending on the mood state of the individuals with BD, (since participants were using cannabis at 
different stages of their illness).  
Data to support this prediction can also be drawn from the self-report literature (36, 37) which will 
be discussed further in the next section. Individuals have reported using different substances at 
different times to manage symptoms of their conditions. However there is currently no data to 
indicate whether such self-reported “self-medication” represents an increase in their typical use.  In 
the two studies mentioned above (34, 35) data for cannabis use has been dichotomised to being 
present or absent, regardless of quantity or frequency of use. In future studies it would be 
important to investigate how amount and frequency fluctuate as a function of mood.   
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Hypothesis 2:  Substance abuse is an attempt by individuals with BD to self-medicate symptoms  
For substance abuse in general, several theorists have suggested a ‘self-medication hypothesis’, 
where patients attempt to reduce the intensity of their symptoms through using particular 
substances (7, 11, 12, 38). As regards to BD, this hypothesis assumes that when the symptoms such 
as hyperactivity, restlessness, over-excitability and poor sleep (that often characterise mania) 
become unbearable then individuals may turn to alcohol or cannabis for their sedative effects, to 
relieve symptoms or reduce the tension or anxiety related to their mood state. Similarly when 
individuals feel low, hopeless and worthless, they may use stimulants (e.g. cocaine or ecstasy) to 
enhance their mood, self-esteem and confidence. 
In their paper, Strakowski and DelBello (7) state that this second hypothesis leads to two 
predictions:  
[1] that substance abuse occurs after the onset of BD (c.f. Hypothesis 1) 
[2] that the specific type of substance is state dependent, whereby an individual uses 
different drugs according to their specific properties, depending on mood state 
As previously discussed, data from studies reviewed so far is inconsistent as regards to the onset of 
cannabis use and BD. One study (28) did find that cannabis use commenced after the onset of BD 
symptoms, which lends some support to the prediction.  This was limited to sub-threshold manic 
symptoms. Additionally whilst those meeting criteria for cannabis abuse and dependence at 
baseline were excluded, they did not control for potential confounders or explore for reverse 
causality. 
However, despite there being only a limited number of studies bearing on cannabis use and BD they 
nonetheless contain evidence to support the suggestion that cannabis use predates the onset of 
BD, which does not support the first prediction. Van Laar et al (31) used participants with no prior 
mood disorders and found that any level of cannabis use at baseline predicted first incidence of BD. 
Additionally, Henquet et al, (29) and Tijssen et al (32) also used participant samples with no prior 
mood disorders and found significant associations between cannabis use at baseline and the onset 
of BD symptoms at post baseline. These associations remained significant even when adjusted for 
potential confounders 
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Strakowski and DelBello (7) provide one explanation for substance abuse appearing to occur prior 
to the onset of BD. They suggest that in fact substance abuse may begin very early in the onset of 
BD during the prodromal or sub-syndromal phases. They argue that individuals may be masking the 
affective symptoms so that it appears their substance use occurs before the onset of BD, when in 
fact, it does not. Data from the Zurich study (28) lends some support to the masking hypothesis 
where cannabis use occurred after the onset of sub-threshold mania (defined as either a duration 
of less than 4 days, or as less than 4 symptoms with impairment), suggesting perhaps that 
individuals were indeed in the prodromal/ sub-syndromal phase when they began using cannabis.   
The second prediction for the ‘self-medication’ hypothesis is that the specific type of substance 
used is state dependent, by which individuals use drugs with specific properties, depending on 
mood state. A review paper of this area (39) focused on the therapeutic use of cannabis or 
cannabinoids in BD, suggests that key constituents of cannabis, THC and cannabidiol (CBD) may 
have mood stabilising properties. The authors found no systematic studies of cannabinoids in BD, 
but they do propose that cannabinoids; THC and CBD may produce a range of sedative, hypnotic, 
anxiolytic, anti-depressant, and anti-psychotic effects. They also suggest that the use of 
cannabinoids warrants controlled clinical trials to investigate their therapeutic potential. This would 
mirror studies of patients with acute and chronic pain conditions and those with multiple sclerosis 
(40, 41), where patients reported improvements in the severity of their symptoms and of their 
mental health.  
Grinspoon and Bakalar (36) provided 5 case histories, which indicated that patients commented 
that they found cannabis to be useful in the treatment of their BD. They reported that patients 
found using cannabis helped relax and control manic behaviour and relieved the effects of other 
medication. Similarly Gruber et al (37) described cases where cannabis appeared to have a direct 
anti-depressant effect, based on self-reports. In the cases of 3 patients with BD, cannabis was found 
to be superior to anti-depressants in relieving their depression. However this should be interpreted 
with caution due to the small sample size and potential bias produced from using data that has 
been unsystematically collected.  
A recent systematic qualitative study (42) utilising semi-structured interviews, had findings differing 
with Gruber et al (37). They reported that cannabis was not always perceived as useful when 
individuals were depressed due to its association with mood enhancing qualities. They also found 
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that patients’ reasons for using cannabis were idiosyncratic. Some used it to alleviate and reduce 
symptoms of mania, whilst others used it prior to entering a manic state and once elated, felt 
satisfied and experienced a decreased need for cannabis.   
The findings from the self-report literature indicate that individuals appear to use cannabis when 
both manic and depressed for a variety of reasons. This may contradict the second prediction of 
Strakowski and DelBello (7) that individuals use different drugs, depending on their mood state. 
However individuals with BD may use cannabis in discrete mood states due to the various 
pharmacological properties it may contain, as noted by Ashton et al (39). Whilst manic, people may 
use cannabis for the sedative effects and when depressed, for the anti-depressive effects proposed 
by Ashton et al (39).  
If true, the suggestion that cannabis may produce anti-depressant effects could cause additional 
complications for individuals with BD. Anti-depressants have previously been associated with the 
induction of manic episodes (43, 44, 45), additionally impacting on the course of the illness (46). 
Anti-depressant effects exerted by cannabinoids could have the potential to induce manic-like 
episodes. A number of case studies have presented patients who appeared to experience manic 
symptoms following cannabis use (47, 48, 49).  
Links between cannabis use and manic symptoms are consistent throughout the literature. 
Exploring causality, Henquet et al (29) and Tijssen et al (32) found cannabis use at baseline 
predicted later onset of manic symptoms. Over the course of BD, Baethge et al (35) found cannabis 
use preceded and also coincided with manic morbidity but did not follow a change in mood state.  
A further investigation into the effect of cannabis use on the symptoms of people with BD is 
indicated. A recent study (50) used experience sampling methodology (ESM) to investigate the 
effects of cannabis use on psychotic symptoms and mood in individuals with psychosis and a non-
clinical sample, over the course of daily life. For individual’s with BD, tracking the daily patterns of 
cannabis use and affective symptoms may provide insight into the range of effects which have been 
reported in the literature - for example whether cannabis use leads to an increase in manic or 
depressive symptoms or whether a change in affective symptoms leads to an increase or decrease 
of cannabis use.  
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Hypothesis 3: Substance abuse causes BD 
The third hypothesis for why substance abuse is so common in individuals with BD is that substance 
abuse may in fact cause the illness. The effects of substance use have been noted to imitate 
affective disorders (9). The euphoria and elation brought on by stimulants, mirrors the high of 
mania, which is typically followed by post drug effects such as low mood and lack of energy, which 
are characteristic of depression.  
Strakowski and DelBello (7) hypothesise that firstly substance abuse may directly cause symptoms 
that resemble BD or secondly may actually initiate BD in vulnerable individuals who might not 
otherwise have developed the illness. For this hypothesis Strakowski and DelBello (7) make 3 
further predictions: 
[1] substance abuse begins prior to onset of BD  
[2] there is less familial affective illness in people with BD with substance abuse than those 
without  
[3] BD will resolve once substances are no longer abused 
As noted earlier in this review, there appears to be conflicting evidence regarding the sequencing of 
onset of cannabis use and BD. From reviewing the current research there appears to be more 
evidence to suggest that cannabis use begins prior to the onset of BD (29, 31, 32) which supports 
the first prediction. However there is some evidence to suggest that cannabis use does commence 
after the onset of BD symptomology (28).  
The second prediction proposes that if substance use causes BD in people that might not have 
developed the illness otherwise, then those people should demonstrate lower rates of BD in their 
relatives, than those who do not use substances. Unfortunately no studies to date have investigated 
the use of cannabis exclusively in relation to rates of familial BD. 
The third prediction relating to substance abuse causing BD, states that once substance use is 
resolved then affective symptoms should cease. Few studies have examined the longitudinal course 
of co-occurring BD and cannabis use. As discussed previously Strakowski et al (34) studied the 
course of BD and cannabis use disorders after a first psychiatric hospitalisation for mania. Seventy 
percent of the participants did not resume cannabis for at least 8 weeks following discharge, which 
provides some support for this prediction. However authors found the recurrence of cannabis 
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abuse was rapid and common. In addition, 16 patients developed a new cannabis use disorder 
during follow-up, though it is not clear whether this was triggered by a change in their affective 
symptoms during this period.  
The second element of the third Strakowski and DelBello (7) hypothesis suggests that substance use 
may initiate BD in vulnerable individuals who might not otherwise have developed the illness. 
Unfortunately they do not define vulnerability, though one can assume this refers to those who 
have an additional risk factor (e.g. biological) that may make them more susceptible to developing 
BD or BD symptoms if they use substances.  
Unfortunately, none of the studies included in the review have investigated if there are any specific 
risk factors which make individuals who use cannabis more vulnerable to developing BD, than those 
who do not go on to develop BD. Research in this area is far more advanced in relation to psychosis 
and cannabis use. Research has identified a number of factors which interact with cannabis use and 
play a causal role in the development of psychosis or psychotic symptoms. These include those 
individuals already vulnerable to pre-existing psychotic symptoms (e.g. 51, 52) childhood trauma 
(53) and individuals that carry the catechol-o-methyltransferase gene (54).  
Strakowski and DelBello’s (7) further view is that substance abuse may affect the course of BD in 
that it initiates either the initial or first few episodes. They suggest this could occur through the 
kindling or sensitisation process suggested by Post et al (55). As noted earlier, neuro-anatomical 
findings suggest CB1 interacts and alters the function of dopamine, which modulates a number of 
areas including affect. It has been proposed that both psychosis and mania may share a genetic 
vulnerability to a dysregulated dopamine system, which may be precipitated by pharmacological 
stress, such as cannabis use (56). The repeated use of cannabis and subsequent production of the 
cannabinoids, may lead to permanent changes in the dopaminergic system in the brain (57, 58). 
This process called ‘sensitisation’ refers to a change in dopaminergic state that may lead to random 
releases of dopamine in the brain.  This, it has been suggested, may contribute to the development 
of psychosis (59, 60).  
Authors have suggested that this same mechanism may apply to mania (29, 31). Therefore once 
there has been a permanent alteration in the central nervous system, individuals will continue to 
display affective symptoms, regardless of continued cannabis use (7). Studies, which have revealed 
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that baseline cannabis use is associated with the later development of manic symptoms, support 
this hypothesis (29, 32).  
However further investigation of these interactions and the role of genetic and environmental 
factors, which may lead to the development of BD, is indicated. Henquet et al (29) suggest such 
studies should focus on individuals who have been exposed to cannabis use and have a pre-existing 
vulnerability to a dysregulated dopamine system.  
 
Hypothesis 4: Cannabis use and BD share a common risk factor 
Strakowski and DelBello’s (7) final hypothesis is that BD and substance use disorders may share a 
common risk factor. For example the genes that cause BD, may also contribute to substance abuse 
(9). Previous studies have found BD and substance use share common risk factors such as elevated 
levels of impulsivity (e.g. 15) sensation seeking (12); co-morbidity with anxiety disorders (61) or 
enhanced Behavioural Activation System (BAS) sensitivity (62). 
A recent study (63) investigated independent predictors for lifetime and recent substance use 
disorders in a sample of patients with rapid-cycling BD. The authors highlight that their study is the 
first to investigate the association between anxiety disorders and recent/ lifetime prevalence of 
particular substances, in a sample of BD individuals. Patients with co-occurring anxiety disorders 
(n=261) had significantly increased rates of lifetime (OR = 3.4, 95% CI: 1.91-6.01, p = < 0.0001) and 
recent (OR=2.5, 95% CI: 1.14 – 5.77, p = < 0.018) cannabis dependence compared to those without 
anxiety disorder (n=303). Specifically, Generalised Anxiety Disorder (GAD) was associated with 
lifetime (OR = 3.36, 95% CI: 1.646 – 6.856, p = 0.0009) and recent (OR=3.28, 95% CI: 1.214 – 8.863, p 
= 0.0191) cannabis dependence. They also found that a history of physical abuse was associated 
with recent cannabis dependence (OR = 3.47, 95% CI: 1.385-8.673, p = 0.0079). These results 
remained significant even when adjusted for potential confounder variables such as gender, age, 
number of episodes, history of alcohol use and psychosis.  
A number of limitations of the study were identified. Not all Axis I anxiety disorders were assessed 
in the study, history for post traumatic stress disorder and social phobia were not available for 
analyses. Therefore whilst an association was revealed between ‘anxiety disorders’, Rapid Cycling 
BD and cannabis dependence, results may not generalise to all types of anxiety. Data from the 
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study was cross sectional, so whilst a relationship between anxiety disorders, in particular GAD and 
cannabis dependence was revealed, causality cannot be established. A longitudinal prospective 
study is indicated to investigate this further. Additionally, as the authors noted, differences 
between BD patients with rapid cycling BD and without have been reported (64, 65), therefore 
findings from the study may not generalise to other BD populations.  
 Unfortunately no further studies in the review examined whether exclusively cannabis use and BD 
share a common risk factor and thereby providing additional evidence required for this fourth 
hypothesis.  However a number of studies reviewed have found evidence to suggest that co-
occurring BD and cannabis use are in fact a risk factor for poorer outcomes; including increasing 
severity of symptoms and non-medication compliance, compared to BD alone.  
A prospective observational study (66) of both inpatients and outpatients with BD, aimed to 
investigate the exposure of cannabis use on clinical and social treatment outcomes over the course 
of one year. During this time period, cannabis users exhibited less compliance and higher overall 
symptom severity (mania and psychosis symptoms) in comparison to the non-users. Furthermore, 
cannabis users experienced less satisfaction with life and experienced a lower probability of 
developing a relationship.  
A recent prospective observational study (67) investigated factors that influenced medication 
adherence in people with BD during initial uptake or a change in treatment. They found that the 
patients less likely to comply with medication adherence were those with cannabis 
abuse/dependence during the first 12 weeks of treatment.  
Unfortunately, due to the nature of the designs, it is impossible to determine true causality in either 
of the 2 studies (66, 67). Therefore whilst significant differences were revealed between users and 
non-users, it is impossible to affirm that this was due solely to the effects of cannabis use.  
Investigating neuro-physiological links between co-morbid cannabis use and BD, Jarvis et al (68) 
compared brain morphometry between BD adolescents with co-occurring cannabis use disorders 
and without. Using whole brain structural magnetic resonance imaging scans (MRI) they found 
adolescents with co-occurring BD and cannabis use demonstrated evidence of greater structural 
abnormalities in the frontal and temporal cortical areas, as well as in the sub-cortical regions, linked 
to emotional and motivational regulation. Due to the cross-sectional nature of the study, it remains 
difficult to ascertain causal inferences from the results, though they do tentatively suggest there 
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may be underlying differences involved in cannabis use. This research may provide clues to the 
possible reasons for non-compliance (66, 67), as repeated cannabis use may affect an individual’s 
motivation and ability to make decisions about taking their medication, which in turn may have an 
affect on their symptom severity and future outcomes.  
Whilst a number of methodological issues were raised,  Gao et al (63) provide evidence to suggest 
co-occurring rapid-cycling BD and cannabis use may share common risk factors such as anxiety 
disorders (specially GAD) and past physical abuse.  This mirrors results from previous studies which 
have found high levels of co morbidity of anxiety disorders in individuals with BD and substance use 
in general (61).  Further research is needed to explore whether individuals with co-occurring BD and 
specifically cannabis use may share other common risk factors (e.g. impulsivity), like substance use 
in general. Additionally a number of studies (66, 67, 68) appear to suggest that the co-occurrence of 
BD and cannabis use may increase the risk of a range of difficulties being experienced and reduce 
the likelihood of positive outcomes, compared to BD alone.  
 
SUMMARY 
 Thirteen studies reporting on the relationship between BD and cannabis use were examined and 
critically reviewed. The studies vary considerably with regards to the methods and samples used, 
ranging from case series (e.g. 36) to longitudinal prospective studies (e.g. 29) and individuals with 
sub-threshold manic symptoms (e.g. 28) to those with a DSM-IV (27) diagnosis of BD disorder (e.g. 
35).  
A number of limitations were highlighted throughout the review. Firstly, 4 of the 13 studies 
reviewed used sub-threshold symptoms of BD (28, 29, 35, 32), based on existing literature which 
suggests that there are expressions of mania distributed within the general population (69, 70). 
However this may lead to an overestimation of associations reported in these studies when 
compared to those that include individuals with a clinical diagnosis of BD.  
The identification participant’s level of cannabis use/abuse/dependence varied throughout the 
studies. Some studies required a SCID diagnosis or cannabis abuse or dependence (e.g. 28, 35, 68), 
whilst in others lifetime use was determined as 5 times or more at baseline (31, 32). The diagnostic 
instrument used for assessment varied throughout the studies, some used the SCID (e.g. 34, 35, 68) 
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others used the CIDI (e.g. 29) and one study used the Structured Diagnostic Interview for 
Psychopathologic and Somatic Syndromes (e.g. 28). However, all the above instruments were based 
on either DSM-III (33) or DSM- IV (27) criteria.  
All of the studies relied on self-report data, which may lead to underestimations due to the illegal 
nature of drug use. Hair sample analysis may be a more reliable method of assessment in future 
research (71). The studies did not report on the type of cannabis used and data indicates that level 
of THC (the major psychoactive compound in cannabis) varies depending on type of cannabis (72, 
73). In one study (28) data was collected over a number of decades. Reports indicate that the 
concentration levels of THC found in cannabis have risen over time (from 9% in 1999 to 18% in 
2005) according to Niesink et al (74).  
Despite the limitations already discussed, studies reviewed here do provide further evidence both 
for and against Strakowski and DelBello’s (7) original hypotheses. Like Strakowski and DelBello’s (7) 
findings, there appear to be a number of factors that contribute to the high occurrence of BD and 
cannabis use and specific reasons for this co-morbidity remain equivocal. There is a conflict in 
evidence regarding the sequencing of onset of BD and cannabis use. However from reviewing the 
available research, there appears to be more evidence to suggest that cannabis use begins prior to 
the onset of BD (29, 31, 32). This fails to support the prediction that substance use originates as a 
way of coping with BD (‘the self-medication’ hypothesis), since in many cases cannabis use occurred 
before the onset of BD. However the self-report literature indicates that patients do indeed find 
cannabis useful in the treatment of their BD.  Whilst cannabis use was perceived as helpful in the 
management of BD, reasons for its use appeared idiosyncratic. 
 Some individuals, for example, appeared to use cannabis when both manic and depressed. This is 
not consistent with the self-medication hypothesis, which states that individuals use different drugs 
depending on their mood state. Reasons for use from the self-report literature are consistent with 
the pharmacological properties of cannabis outlined in a review (39). The paper suggests that THC 
and CBD, the key constituents of cannabis may produce a range of effects (39). Therefore whilst 
manic, individuals may use cannabis for the sedative effects and when depressed for the anti-
depressive effects.  
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Links between manic symptoms and cannabis use were consistent throughout the literature (29, 32, 
35). One possible explanation for this is that cannabis use can induce mania, though this requires 
further investigation into the pharmacological properties of cannabis and the potential subsequent 
effects. As discussed previously the interaction between CB1 and dopamine can lead to a 
permanent change in the central nervous system and may have important consequences for 
individuals with BD.  
The studies reviewed have made a significant contribution to our understanding of co-occurring 
cannabis use and BD. However, the literature review has highlighted a lack of research focused 
specifically on cannabis use and BD. There are a number of areas which warrant further attention.  
Research should focus on whether there are additional factors which interact with cannabis use and 
make individuals more ‘vulnerable’ to developing BD. This includes an investigation of the 
interaction between THC and dopamine in the brain and whether this leads to the development of 
BD or whether it further complicates affect regulation. The relationship between cannabis use and 
BD also requires further investigation - whether individuals are using cannabis to self-medicate a 
change in symptoms or whether cannabis use itself leads to a change in symptoms.  Additional 
research in this area may offer a clearer understanding of why there are such high levels of 
cannabis use in individuals with BD. 
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PREFACE 
This work for this paper was completed between January 2010 and May 2011. A number of 
individuals made significant contributions towards the research study. Firstly, Professor Christine 
Barrowclough provided overall support and supervision for the study. She also read the manuscript, 
gave advice and was involved in the formulation of items for the experience sampling diary. 
Professor Steven Jones was the field supervisor for the study and was also involved in the 
formulation of the items for the experience sampling diary. Miss Nancy Black assisted with the 
identification and recruitment of research participants for the study. Miss Lesley-Anne Carter 
provided statistical support and supervision for the study.   
The author intends to publish the research paper in ‘Bipolar Disorders - An International Journal of 
Psychiatry and Neurosciences’ and the paper has been prepared in accordance with their 
requirements (see appendix A for author guidelines). The authors on this paper will be: Elizabeth 
Tyler, Professor Christine Barrowclough, Professor Steven Jones, Nancy Black and Lesley-Anne 
Carter.  
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ABSTRACT 
Objectives: Although cannabis use is common in bipolar disorder (BD) and may contribute to worse 
clinical outcomes, little is understood about the relationship between this drug and BD over the 
course of daily life. 
Methods: Twenty-three participants with BD type I or type II completed diaries for 6 days using 
Experience Sampling Methodology to provide a close investigation into the associations between 
cannabis, mood, BD symptoms and Behavioual Activation System (BAS) sensitivity. Self-reported 
BAS was also measured and the extent to which this predicted changes in mood, BD symptoms and 
cannabis use.  
Results: The results indicated that positive affect predicted the likelihood of subsequent cannabis 
use (OR:1.25 ,CI:1.06–1.47, P=0.008). However, neither negative affect, manic nor depressive 
symptoms predicted the use of cannabis. Cannabis use was associated with subsequent increases in 
positive affect (β=0.35, CI:0.20-0.51, P=0.000), manic symptoms (β=0.20,CI:0.05-0.34, P=0.009) and 
depressive symptoms (β= 0.17,CI:0.04-0.29, P=0.008). BAS sensitivity (ESM diary) was associated 
with increases in positive affect (β=0.18, CI:-0.09-0.26, P=0.000) and manic symptoms 
(β=0.27,CI:0.19-0.35, P=0.000). Similarly a higher self-reported BAS (questionnaire) was associated 
with increases in positive affect (β = 0.06, CI: 0.02–0.89, P=0.001) and manic symptoms (β = 0.08, CI: 
0.04–0.12, P=0.000). 
 Conclusion: The findings indicate that cannabis use is associated with a number of psychological 
effects, however no evidence for the self medication of mood and BD symptoms was revealed in 
daily life. Associations between BAS sensitivity and positive and manic symptoms are consistent 
with current literature. The findings in relation to existing literature and clinical implications are 
discussed in the paper.  
 
Keywords: bipolar disorder, mania, cannabis use, experience sampling methodology, ESM, 
behavioual activation system, self-medication.  
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INTRODUCTION 
Cannabis is the drug most frequently used by individuals with Bipolar Disorder (BD: 1, 2, 3). 
Estimates of current use range from 8% to 22% and lifetime use from 30% to 64% (4). In comparison 
to BD alone, co-occurrence with cannabis use is a risk factor for poorer outcomes, including 
increased symptom severity (5) and poorer medication compliance (5, 6). Therefore individuals with 
co-morbid BD and cannabis use represent an important group to study from both a clinical and a 
public health perspective.  
Specific reasons for this co-morbidity remain equivocal and are not yet fully understood. A number 
of prospective cohort studies (7, 8, 9) have found evidence to suggest that cannabis use begins prior 
to onset, which might suggest a causal role in the development of BD. However there is also 
evidence to suggest that for some, cannabis use commences following the onset of BD 
symptomatology (10).  The self-report literature suggests that individuals with BD use cannabis as a 
form of self-medication to alleviate manic symptoms (11, 12) and to relieve depression (13). These 
studies (11, 12, 13) suggest that individuals with BD may use cannabis for the differing 
pharmacological properties outlined by Ashton et al (14) who proposed that ∆9-
tetrahydrocannabinol (THC) and cannabidiol (CBD), (the key constituents of cannabis) may produce 
a range of effects (e.g. sedative, anxiolytic, antidepressant). Therefore whilst manic, individuals may 
use cannabis for the sedative effects and when depressed for the anti-depressive effects.  
In accordance with the Behavioural Activation System (BAS) hypersensitivity model of BD (15, 16), 
the high rates of BD and substance use reported may be partially due to a hyper-reactive BAS. The 
model suggests that vulnerability to BD may be reflected in an overly sensitive BAS that is hyper-
active to relevant cues such as reward incentive or goal striving (17). It is therefore hypothesised 
that excessive BAS activation and increased sensitivity can lead to hypo(manic) symptoms such as 
euphoria, optimism, distractibility,  excessive goal seeking and increased self-confidence (15, 18). 
Alloy et al (19) hypothesise that high BAS activation should also be associated with greater 
substance abuse, which occurs as a product of an individual’s pursuit for rewarding stimuli (i.e. 
drug-induced ‘highs’). They found that higher BAS sensitivity, measured by the BIS/BAS scale (20), 
predicted BD status and increased substance use difficulties.                                   
A number of factors appear to contribute towards the high level of cannabis use reported in BD. 
Similarly, rates of cannabis use in individuals with psychosis are high (21, 22) and there is no single 
model available which fully explains this co morbidity (23). A recent study (24) used the experience 
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sampling method (ESM) to provide further insight into the complicated dynamics of cannabis use 
and its effect on individuals with psychosis, in the context of daily life. Henquet et al (24) found that 
cannabis use predicted an increase in positive affect in both individuals with psychosis and a non-
clinical control group. Cannabis use predicted a decrease in negative affect and an increase in the 
number of hallucinatory experiences in the psychosis group alone. They found no evidence to 
support the self-medication hypothesis as neither psychotic experiences or mood was found to 
predict cannabis use. Similarly to Henquet et al (24), the current study was designed using ESM to 
allow a close investigation into BD and cannabis use over the course of daily life and to aid further 
understanding of this seemingly complex relationship.  
ESM is a structured diary method where individuals are asked to report their thoughts, feelings and 
symptoms over the course of daily life. ESM was pioneered in mental health research by a group of 
researchers at the University of Maastricht (25, 26). It offers a number of advantages in comparison 
to traditional assessments of mental health experiences (27, 28), which rely on using retrospective 
data, and may be open to recall bias. With ESM, the short space between an event occurring and 
reporting of the details reduces the possibility of memory bias (29). ESM examines phenomena in 
the real world as they occur and therefore has a high level of ecological validity. It provides a rich 
and descriptive data set, detailing a participant’s daily experience and has the capacity to assess the 
temporal relationship between numerous variables (28). 
ESM has previously been used to investigate the perception of daily ‘hassles’ and ‘uplifts’ in 
individuals with BD (30). Furthermore, Knowles et al (31) used a diary method, where individuals 
with BD or unipolar depression plus a non-clinical sample reported on self-esteem and positive and 
negative affect twice a day, over the course of a week.  
To the author’s knowledge there are no published studies that have used ESM to examine the 
relationship between BD and cannabis use. In the current study, the use of ESM aimed to provide 
an in-depth investigation into the associations between cannabis use, mood, BD symptoms and BAS 
sensitivity in individuals with BD, over the course of daily life, and to test a number of predictions 
suggested in the literature outlined above.  
The aims of the study were to explore whether:  
1]      the frequency of cannabis use would increase as a function of mood and BD symptom 
change (i.e. self medication effects) 
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2]     cannabis use would be associated with subsequent changes in mood and  BD symptoms 
 
3] an increase in BAS sensitivity (measured by the questions in the ESM diary) would lead to 
an increase in manic symptoms and / or cannabis use 
 
4] individuals scoring higher on the BAS total, (from the BIS/ BAS questionnaire; 20) would 
experience higher levels of manic symptoms and were more likely to use cannabis 
 
METHOD 
Participants 
Ethical approval for the study was obtained from the National Health Service (NHS) and the 
University of Manchester research ethics committees. Twenty-seven participants were recruited for 
the study from a number of sources. These included 4 mental health trusts in the North-West of 
England, self-help organisations (Manic Depression Fellowship and Mood Swings), self-referral from 
the online University of Manchester research volunteering website and from the PARADES1 
participant panel (a confidential database of individuals with BD who have taken part in previous 
PARADES research and have expressed an interest in taking part in further research).  
All individuals met criteria for BD-I or BD-II, as determined by the Structured Clinical Interview for 
Axis I Disorders (SCID) based on the DSM-IV diagnostic criteria (32). Researchers were trained in the 
SCID and received regular supervision from a consultant psychiatrist. Substance use disorders were 
assessed using the substance use module of the SCID (32). To be included, participants were 
required to report using cannabis on at least two occasions per week (in at least half the weeks in 
the 3 months prior to assessment). Exclusion criteria for the study included meeting criteria for a 
current episode of mania or depression (if currently met criteria they were kept on a waiting list 
until out of episode), aged below 18, evidence of an organic brain disease or moderate to severe 
learning disability. 
                                                          
1 The study is part of the PARADES programme, Spectrum Centre, University of Lancaster, funded by the National Institute for Health 
Research. A research programme focused on BD and comorbid problems.  
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Power calculations are difficult and complicated to estimate in ESM analyses due to the multi-level 
nature. This is because there is a sample size for each level and therefore statistical power is 
determined at more than one level (33). It was expected that the sample size in the current study 
was nevertheless enough to detect effects.  
 Experience Sampling Method 
At the beginning of this study, participants were given a paper diary and a digital wristwatch. In 
accordance with previous research (e.g. 34, 35), the ESM period lasted for six consecutive days and 
the watch emitted a signal on ten occasions throughout the day at pseudo-random times, between 
the hours of 8am and 10pm.  
Each time participants heard the beep they were required to fill out a page of the diary. The diary 
consisted of questions on thoughts, mood, BD symptomatology, BAS sensitivity, contextual 
information regarding their current situation and substance use. Participants were required to fill 
out the diary within 15 minutes of hearing the beep and to record the time of completion. Any 
entries completed outside this time frame were excluded from analyses. Previous research has 
demonstrated that entries completed after the 15 minutes are less reliable and valid (26). A 
minimum of 20 valid diary reports were required by each participant, to ensure the data was 
representative (28). 
Procedure  
During the initial visit informed consent was gained from the participant and the SCID (32) interview 
was completed. Where all inclusion criteria were met, a second visit was arranged, one day prior to 
the ESM period. During the second visit, the participant was introduced to the watch and paper 
diary and briefed about the study. The general procedure described above was explained in detail.  
During the briefing session the researcher discussed the layout of the diary in detail and asked the 
participant to fill out a trial page. Each response was checked carefully, thus ensuring that the 
participant fully understood what was required.  
The researcher left contact details with the participant in case any queries arose regarding the 
study. Participants were contacted via telephone and text message twice during the 6-day ESM 
period in order to facilitate motivation and discuss any queries regarding the study.  
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On the seventh day a final meeting was arranged to collect the watches and diaries and debrief the 
participant. The diaries were checked for any ambiguity and whether the participant had completed 
20 or more entries.  Information was recorded on whether it had been a typical week and if the 
experiment had influenced their mood, cannabis use and usual activities.  Participants filled out the 
BIS/BAS scale (20) at this final meeting. 
 
MEASURES 
The experience sampling diary 
Mood items 
Current mood was assessed using ten items, rated on a 7-point Likert scale (where 1= ‘not at all’ 
and 7 =’ very much so’). Items were drawn from previous ESM studies (34, 36) using participants 
with psychosis and healthy controls. A principal components analysis revealed two separate scales: 
the items ‘cheerful’, ‘excited’, ‘relaxed’, ‘satisfied’, ‘happy’ formed the positive affect scale (∝ = 
0.85) and the items ‘lonely’, ‘anxious’, ‘irritate’, ‘sad’, ‘guilty’, formed the negative affect scale (∝ = 
0.82). The mean scores for each scale were used in the analyses.  
BD Symptoms 
Current BD symptomatology (mania and depression) was assessed using 7 items rated on a 7-point 
Likert scale. The formulated items were chosen in accordance with guidelines for selection of ESM 
items (28) and to assess momentary experiences of BD symptoms that might occur and fluctuate 
during the flow of daily life. A service-user group of 4 people with a BD diagnosis verified the 
appropriateness of the questions and members felt the language reflected how they would 
describe their own behaviour and experiences. A principal components analysis revealed two 
distinct subscales. The mania scale (∝ =0.75) consisting of the items: I am ‘full of energy’, ‘high’, 
‘good ideas’ and the depression scale (∝ = 0.82), consisting of items: I feel ‘slowed down’, ‘low’, 
‘bad about myself’, ‘fearful’. The mean scores for each scale were used in the analyses.  
BAS sensitivity  
Current BAS sensitivity was assessed using three items rated on a 7-point Likert scale. The mean of 
these items was used to form the ‘BAS sensitivity scale’ (∝ = 0.76), consisting of items: ‘I want to try 
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something new’, ‘Nothing can stand in my way’ and ‘I’m craving excitement’. The mean scores for 
the scale were used in the analyses.  
Substance use 
Cannabis use, referred to as a ‘cannabis moment’ was reported in the diary after each beep (the 
period between the current beep and previous beep) from the question ‘since the last beep I’ve 
used cannabis?’ Cannabis use previous was defined as cannabis use during the period between 
previous beep and the beep before that. The type of cannabis used was also recorded.  
Alcohol and other drug use (other than cannabis) were reported in the diary after each beep, 
termed ‘alcohol moment’ and ‘other drug moment’ respectively.   
 
Questionnaire 
BIS/ BAS scale (20) 
The BIS/BAS scale (20) is a 20-item measure consisting of three BAS subscales: Reward 
Responsiveness (RR), Drive (D) and Fun Seeking (F) and one Behavioural Inhibition System (BIS) 
scale. Each item has four possible options ranging from “strongly disagree” to “strongly agree”. The 
scale measures an individual’s tendency to respond to threatening events with fear, anxiety or 
negative affect. It includes items such as ‘I feel pretty worried or upset when I think or know 
somebody is angry at me’. Overall the BAS scale measures positive affect and motivation in 
response to incentives or rewards. The RR subscale assesses positive affect in response to expected 
or experienced desired events, e.g. ‘it would excite me to win a contest’. The D subscale measures 
individuals motivation to pursue desired goals such as ‘I go out of my way to get what I want’. The F 
subscale measures willingness / impulsivity to pursue or approach novel and rewarding stimuli, e.g. 
‘I will often do things for no other reason than they might be fun’. Carver and White (20) report 
internal consistencies of between (α’s) from .59 to .74 for the subscales.  
The scale has been widely used to measure individual differences in sensitivity of the BAS and the 
BIS in a number of populations including community samples (37) depressed mothers (38) and BD 
spectrum disorders (16, 19, 39).  
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Two studies (37, 40) found factor analyses supported a two-factor structure reflecting separate 
behavioural inhibition (BIS) and behavioural activation systems (BAS). The BAS total (consisting of 
the 3 subscales; RR, D and F) was used in the present study, the internal consistency in the present 
sample was, α = 0.76 (BAS total).  
 
STATISTICAL ANALYSIS STRATEGY 
STATA 11 (41) was used for the analyses.  ESM data has a hierarchical structure with the repeated 
participant observations (level one), nested within days (level two), nested within participants (level 
three).  Responses for one individual or for one day are more likely to be similar than those for a 
different individual or for a different day. Multilevel random regression analysis was used as it takes 
the whole data set into account and can estimate the amount of variation that is associated with 
the three different levels. The multilevel regression XTMELOGIT routine was used for the 
dichotomous variables and the XTMIXED routine for the continuous variables. Therefore the odds 
ratios (dichotomous variables) and the betas (continuous variables) are the associations between 
the independent and dependent variables in the multilevel model. Figure 1 demonstrates the main 
analyses conducted.   
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EXPERIENCE SAMPLING METHOD TIME-LINE 
 
 
Preliminary analyses 
Multi-level regression analyses were conducted to identify whether age, gender, alcohol use at the 
same beep, other drug use at the same beep, type of cannabis used and total cannabis use for the 
ESM period were associated with changes in mood, BD symptoms and cannabis use. The results 
were used to identify which variables would be adjusted for in the main analyses.   
 
Self medication effects (See Figure 1 – Analysis A) 
To investigate whether mood or BD symptoms predicted cannabis use; multilevel analyses were 
conducted using the XTMELOGIT routine. Positive affect previous, negative affect previous, mania previous 
 
 
Cannabis 
use 
Positive affect previous 
Negative affect previous 
Mania previous 
Depression previous 
 
Positive affect  
Negative affect  
Mania 
Depression 
BAS previous 
 
 
Cannabis 
use previous 
A B 
C 
D 
Previous beep Current beep 
Figure 1: STATISTICAL ANALYSES -Adapted from Henquet et al (24) A: analysis to investigate self medication effects, with positive affect previous, negative 
affect previous, mania previous and depression previous as the independent variables and cannabis use as the dependent. B: analysis to investigate the effects of cannabis with 
cannabis use as the independent variable and positive affect, negative affect, mania and depression as the dependent variables. C: analysis to investigate the effects 
of BAS, with BASprevious as the independent variable and cannabis use, negative affect, positive affect, mania and depression as the dependent variables. D: analysis of 
temporal dynamics of cannabis effects to investigate the short and long term effects of cannabis use.   
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and depression previous were entered as the independent variables and cannabis use as the 
dependent variable.  Overall cannabis use during the ESM week was adjusted for in these analyses.  
 
Cannabis effects on mood and BD symptoms (See figure 1 – Analysis B) 
The main effects of cannabis use on mood / symptoms were investigated with cannabis use as the 
independent variable and positive affect, negative affect, mania and depression as the dependent 
variables.  Alcohol use at the same beep and overall cannabis use during the ESM week were 
adjusted for in these analyses. 
 
BAS sensitivity effects on cannabis use, mood and BD symptoms (See figure 1 – Analysis C) 
The main effects of BAS sensitivity on mood / symptoms were investigated with BAS previous as the 
independent variable and positive affect, negative affect, mania and depression as the dependent 
variables.  Alcohol and cannabis use at the same beep and overall cannabis use during the ESM 
week were adjusted for analyses.  
To investigate the effect of BAS sensitivity on cannabis use, BAS previous was entered as the 
independent variable and cannabis use as the dependent variable. 
 
Temporal analyses of cannabis use (See figure 1 – Analysis D)   
Post hoc analyses were conducted to further investigate the duration of cannabis effects on mood 
and symptoms. To investigate these, cannabis use at the current beep and cannabis use previous were 
entered simultaneously into the model, predicting positive affect, negative affect, mania and 
depression.  
 
 
 
55 
 
Investigating the association between BAS total score and mood / BD symptoms / cannabis use 
To investigate associations between the BAS total and mood and symptoms, BAS total was entered 
as the independent variable and positive affect, negative affect, mania and depression as the 
dependent variables.   
RESULTS 
Participants  
Twenty-seven participants initially participated in the study. However 2 participants were 
subsequently excluded as they had fewer than 20 valid reports and a further 2 dropped out due to 
personal circumstances. The final study sample consisted of 23 participants, 16 males and 7 females 
(mean age 36.8, SD: 12.8). Twenty-one of the participants met criteria for BD-I and 2 met criteria for 
BD-II. The majority of the participants (87%) were from a white British background and over half of 
the sample (56%) was unable to work due to their mental health difficulties. Six of the sample had a 
current co-morbid anxiety disorder and 5 had a current co-morbid personality disorder. See table 1 
for further demographic details of the participant sample. 
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Table 1: Socio-demographics of the participant sample (n =23 )  
Gender (F:M) 7:16 
Age   Mean (SD) 36.8 (12.8) 
Diagnosis (BD I: BD II) 21:2 
Ethnicity 
   White British 
   Other White Background 
   Black Caribbean  
   White and Asian 
 
20 (87.0%) 
1 (4.3%) 
1(4.3%) 
1(4.3%) 
Living status 
    Living alone 
    Living with friends  
    Living with partner and/or children 
    Living with close relative 
 
12 (52.2%) 
5 (21.7%) 
5(21.7%) 
1(4.3%) 
Occupation 
   Sick/ Disability 
   Student 
   Employed/ self employed 
   Employed voluntary 
   Unemployed 
 
 
13 (56.5%) 
4 (17.4%) 
3 (13.0%) 
2 (8.7%) 
1(4.3%) 
Co-morbidity 
 Anxiety disorders * 
 Personality disorders ** 
 
 Current                      
 6 (26.1%) 
 5  (21.7%)             
  
 
* Anxiety disorders included panic disorder (with and without agoraphobia), generalised anxiety disorder, obsessive compulsive disorder,  
   post traumatic stress disorder, social phobia, specific phobia.  
** Personality disorders included Borderline personality disorder and anti-social personality disorder  
 
Substance use 
Three participants met current criteria for cannabis abuse disorder and 12 met criteria for current 
cannabis dependence disorder. Over the course of the six-day ESM period, the mean number of 
cannabis moments for the sample was 15.4 (SD: 8.6, range: 2 – 30). During this period all 
participants reported only using one type of cannabis.  
Two participants met criteria for current alcohol abuse and one for current dependence. The mean 
number of alcohol moments over the ESM week was 3.5 (SD: 5.6, range: 0-21). One participant met 
current criteria for other drug use and 1 met criteria for other drug dependence. The mean number 
of other drug moments over the ESM period was 0.9 (S.D: 2.5, range: 0-12). See table 2.  
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Table 2:  Substance abuse in the participant sample (n = 23)   
Cannabis 
   Current abuse  
   Current dependence 
 
 
3 (13.0%)  
12 (52.2%) 
 
Type of cannabis used 
   Skunk 
   Resin 
   Grass 
 
12 (52.2%) 
8 (34.8%) 
3 (13.0%) 
Cannabis moments over ESM period 
   Mean (S.D) 
   Range 
 
  15.4 (8.6) 
  2 - 30 
Alcohol 
  Current abuse / dependence 
Alcohol moments over ESM period 
    
  Mean (S.D) 
  Range 
 
2/1 
 
 
3.5 (5.6) 
0-21 
Other drug 
   Current abuse / dependence 
    
Other drug moments over ESM period 
   Mean (S.D) 
   Range 
 
1/1 
 
 
0.9 (2.5) 
0-12 
  
BIS/BAS scale (20) 
The mean BAS total from the BIS/BAS scale (20) was 39.52 (SD 7.7). This score is consistent with 
other BD samples (19, 39).  
Individuals’ scores on the BAS total from the BIS/BAS scale (20) were associated with BAS sensitivity 
from the ESM diary (β = 0.11, 95% CI: 0.06 – 0.16, P = 0.000).  
 
Preliminary analyses 
Total cannabis use for the ESM period (number of cannabis moments) was associated with cannabis 
use at the current beep (β = 0.12, 95% CI: 0.10 – 0.15, P = 0.000), therefore this was adjusted for in 
all the main analyses. Alcohol use (at the same beep) was associated with subsequent increases in 
positive affect (β = 0.44, 95 % CI: 0.17 – 0.72, P = 0.002) and manic symptoms (β = 0.32, 95% CI: 0.06 
– 0.58, P = 0.015), therefore it was adjusted for in the analyses which investigated the effects of 
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cannabis. Figure 2 demonstrates the significant associations that were revealed from the main 
analyses.   
 
 
 
 
EXPERIENCE SAMPLING METHOD TIMELINE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cannabis 
use 
Positive affect 
Mania 
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BAS previous 
 
 
Cannabis 
use previous 
A 
C 
B 
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Positive affect 
Mania 
Depression  
Positive affect previous 
 
 
Figure 2: RESULTS -  A: Positive affect previous predicted the likelihood of cannabis use at the next beep. B: Cannabis use was associated with subsequent 
increases in positive affect, manic symptoms and depressive symptoms. C: BAS previous was associated with subsequent increases in positive affect and manic 
symptoms and a subsequent decrease in depressive symptoms.  
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Self – medication effects (See figure 2 – Result A) 
There was a significant relationship between positive affect previous and cannabis use at the current 
beep. (OR: 1.25, 95% CI: 1.06 – 1.47, P = 0.008).  The odds of cannabis use at the current beep were 
increased for those with higher scores of positive affect at the previous beep. Negative affect previous 
did not significantly predict cannabis use at the following beep (OR: 0.88, 95 % CI: 0.74 - 1.05, P = 
0.147). Similarly no association was found between manic symptoms previous (OR: 1.08, 95% CI: 0.93 - 
1.26, P= 0.291) or depressive symptoms previous (OR: 0.92, 95 % CI: 0.78 - 1.08, P= 0.303) and 
cannabis use. See table 3. 
Table 3: Effect of cannabis use on mood/ BD symptoms (Self medication effects)  
Positive affect OR: 1.25, 95% CI: 1.06 - 1.47, P = 0.008 
Negative affect OR: 0.88, 95 % CI: 0.74 - 1.05, P = 0.147 
Mania scale OR: 1.08, 95% CI: 0.93 - 1.26, P= 0.291 
Depression scale OR: 0.92, 95 % CI: 0.78 - 1.08, P= 0.303 
 
 
Cannabis effects on mood and BD symptoms (See figure 2 – B) 
Cannabis use was associated with subsequent increases in positive affect (β = 0.35, 95 % CI: 0.20 - 
0.51, P=0.000). Cannabis use was also associated with subsequent increases in manic symptoms (β 
= 0.20, 95 % CI:  0.05 - 0.34, P= 0.009) and depressive symptoms (β= 0.17, 95% CI: 0.04 - 0.29, P= 
0.008). Overall, cannabis use had no effect on negative affect (β= -0.01, 95 % CI: -0.13- 0.10, P = 
0.806). (See table 4).  
 
Table 4: Effect of mood/ BD symptomatology on cannabis use  
Positive affect β = 0.35, 95 % CI: 0.20 - 0.51, P=0.000 
Negative affect β= -0.01, 95 % CI: -0.13 - 0.10, P = 0.806 
Mania scale β = 0.20, 95 % CI:  0.05 - 0.34, P= 0.009 
Depression scale β=  0.17, 95% CI: 0.04 - 0.29, P= 0.008 
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BAS sensitivity effects on mood/BD symptoms/ cannabis use (see figure 2 -C) 
BAS previous did not significantly predict the likelihood of cannabis use at the following beep (OR = 
0.99, 95 % CI: 0.80 -1.21, P = 0.907). 
BAS previous was associated with an increase in both positive affect (β = 0.18, 95 % CI: -0.09 - 0.26, P = 
0.000) and manic symptoms (β = 0.27, 95 % CI: 0.19 - 0.35, P=0.000). BAS previous was also associated 
with a decrease in depressive symptoms (β = -0.09, 95 % CI: -0.16 to -0.02, P = 0.014). However 
there was no significant association between BAS previous and negative affect (β = - 0.01, 95 % CI: -
0.08 - 0.06, P = 0.712). See table 5.     
   
Table 5: Effect of BAS sensitivity on subsequent cannabis use/ mood/ BD 
symptoms  
 
Cannabis use OR = 0.99, 95 % CI: 0.80 -1.21, P = 0.907 
Positive affect β = 0.18, 95 % CI: -0.09 - 0.26, P = 0.000 
Negative affect β = - 0.01, 95 % CI: -0.08 - 0.06, P = 0.712 
Mania scale β = 0.27, 95 % CI: 0.19 - 0.35,  P=0.000 
Depression scale β  = -0.09, 95 % CI: -0.16 to -0.02, P = 0.014 
 
Temporal dynamics of cannabis effects  
Follow up post–hoc analyses were conducted to investigate the duration of cannabis effects on 
mood and BD symptoms. This was achieved by entering cannabis use and cannabis use previous 
simultaneously into the model. The results suggested that increases in positive affect were 
observed in the short term (β = 0.29, 95% CI: 0.10 – 0.48, P=0.003 for cannabis use) but not the long 
term (β = 0.01, 95% CI: -0.18 – 0.20, P=0.943 for cannabis use previous). Similarly increases in 
depressive symptoms were observed in the short term (β = 0.18, 95% CI: 0.03 – 0.33, P=0.019 for 
cannabis use) but not the long term (β = 0.11, 95% CI: -0.04 – 0.27, P=0.138 for cannabis use previous). 
See table 6.   
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Table 6: Temporal dynamics of cannabis effects   
Positive affect 
   Cannabis use 
   Cannabis use previous 
 
β =  0.29, 95% CI: 0.10 – 0.48, P=0.003  
β = 0.01, 95% CI: -0.18 – 0.20, P=0.943  
Negative affect 
   Cannabis use 
   Cannabis use previous 
 
β = -0.040, 95% CI: -0.18-0.10, P=0.579 
β= -0.01, 95% CI: -0.15 – 0.13, P=0.925 
Mania scale 
   Cannabis use 
   Cannabis use previous 
 
β = 0.07, 95% CI: -0.10 – 0.24, P=0.393 
β = -0.08, 95% CI: -0.25 – 0.09, P=0.359 
Depression scale 
   Cannabis use 
   Cannabis use previous 
 
β = 0.18, 95% CI: 0.03 – 0.33, P=0.019  
β = 0.11, 95% CI: -0.04 – 0.27, P=0.138  
  
 
Investigating the association between BAS total score and mood / BD symptoms / cannabis use 
A higher reported BAS total was associated with increased positive affect (β = 0.06, 95% CI: 0.02 – 
0.89, P = 0.001) and manic symptoms (β = 0.08, 95% CI: 0.04 – 0.12, P = 0.000). However there was 
no significant association between BAS total and negative affect (β = 0.05, 95 % CI:- 0.02 – 0.11, P = 
0.143)  or depressive symptoms (β = 0.05, 95% CI: - 0.02 – 0.11, P = 0.18).    
There was no significant association between BAS total and cannabis use (β = -0.01, 95% CI: - 0.07 – 
0.05, P = 0.643). See table 7. 
Table 7: The association between BAS total and mood / symptoms / cannabis use  
Positive affect β = 0.06, 95% CI: 0.02 – 0.89, P = 0.001 
Negative affect β = 0.08, 95% CI: 0.04 – 0.12, P = 0.000 
Mania scale β = 0.05, 95 % CI:- 0.02 – 0.11, P = 0.143 
Depression scale  β = 0.05, 95% CI: - 0.02 – 0.11, P = 0.182  
Cannabis use β = -0.01, 95% CI: - 0.07 – 0.05, P = 0.643 
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DISCUSSION 
In relation to the first prediction, positive affect was associated with the increased likelihood of 
cannabis use. However, negative affect, manic symptoms or depressive symptoms did not predict 
the use of cannabis at the subsequent beep. This fails to support the hypothesis that cannabis is 
used to self-medicate symptoms of BD in the context of daily life. In line with the second prediction, 
the findings from the study indicate that the use of cannabis in daily life was associated with 
subsequent increases in positive affect, manic symptoms and depressive symptoms. In addition, the 
data suggests that increases in positive affect and depressive symptoms were only experienced in 
the short-term, as cannabis use at the previous beep did not predict a significant increase in mood 
or symptoms at subsequent time points. In line with the third hypothesis, an increase in BAS 
sensitivity, as measured by the ESM diary, was associated with increases in positive affect, manic 
symptoms and a decrease in negative affect. However in contrast, increases in BAS sensitivity were 
not associated with an increased likelihood of cannabis use. Consistent with the final hypothesis, 
individuals scoring higher on the BAS total from the BIS/BAS scale (20), experienced higher levels of 
manic scores and positive affect, however in contrast to the hypothesis they were not more likely to 
use cannabis. 
 
Cannabis effects 
The findings that cannabis use was associated with an increase in positive affect, manic and 
depressive symptoms is consistent with current literature that suggests cannabis can produce a 
range of psychological effects (42, 43, 44). It has been suggested that the psychological and 
physiological effects of cannabis are primarily due to its main chemical compounds, THC and CBD. 
The effects of cannabis have previously been found to be bidirectional (42, 45), causing effects such 
as euphoria and dysphoria; this may partially explain why cannabis use was associated with both 
manic and depressive symptoms in the current study. The bidirectional effects of cannabis have 
been found to depend on a range of factors such as dose, route of administration and personality 
differences (42, 45).  
The effect of cannabis use on individuals with psychosis has received rather more investigation than 
the effects of the drug on those with BD.  Research suggests that compared to ‘healthy’ control 
participants, individuals with high expressed psychosis liability may be more sensitive to THC (46, 
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47). Barkus and Lewis (48) found that individuals scoring higher on Schizotypal traits were more 
likely to experience both psychosis-like experiences and more pleasurable experiences after 
smoking cannabis. Individual differences in sensitivity to the effects of THC may explain the range of 
experiences (24). In a similar way, individuals with BD may also differ in their sensitivity to the 
effects of THC, which may explain why there was a range of effects in the current study.  
The increase in symptoms following cannabis use in the current study may be due to the effect of 
THC on dopamine levels in the brain. Once ingested, THC replicates the actions of natural 
cannabinoids produced in the body and binds itself to cannabinoid receptors CB1 and CB2, found 
within several regions of the brain. Neuro-anatomical findings suggest CB1 modulates and interacts 
with the function of dopamine (49). The repeated production of cannabinoids, following cannabis 
use may lead to a permanent change in dopamine levels (50, 51). It has been suggested that this 
process called ‘sensitisation’ may contribute to the development of psychosis (52, 53). Authors have 
suggested that this same mechanism may apply to mania (7). However further research in this area 
is clearly indicated as little is understood regarding the underlying interaction between 
cannabinoids and dopamine (54).  
 
Effects of mood / BD symptoms on cannabis use (Self-medication effects) 
Positive affect predicted the likelihood of cannabis use, and it appears that individuals were using 
cannabis when they were feeling good. Alternatively, higher positive affect prior to cannabis use 
may have been experienced due to the expected enjoyment of the effects of substance use.  
Data from the current study does not support the idea that cannabis is used for self-medication 
effects in the context of daily life. An increase in negative affect and BD symptoms did not predict 
cannabis use at the following beep. This finding is consistent with Henquet et al (24) who similarly 
did not find evidence to support the self-medication hypothesis for psychosis, as changes in 
hallucinations, delusions and negative affect did not predict cannabis use.  
The interpretation of the findings of this study is limited to the associations between the current 
beep and the previous beep. It is possibly the case that self-medication effects appear further down 
the chain of events, following a longer period of mood / symptom changes. Alternatively, failure to 
find self-medicating effects from cannabis may have been due to the nature of the participant 
64 
 
sample. BD is characterised by shifts in affect regulation and therefore over time individuals may 
have become accustomed to subtle changes in mood. Therefore, within the context of daily life, 
cannabis may not be used as a way to cope with these slight fluctuations. Participants in the study 
were currently well and out of episode and therefore it may be that cannabis is used to self-
medicate more pronounced symptoms or the onset of manic / depressive episodes. This would be 
consistent with the self- report literature where individuals have found cannabis useful in the 
management of their BD (11, 12, 13).  
Effects of the BAS 
Data from the current study does support the prediction that an increase in BAS sensitivity was 
associated with an increase in manic symptoms. This finding is consistent with the BAS 
hypersensitivity theory of BD (15, 55) which suggests that excessive activation of the BAS is 
reflected in hypo (manic) symptoms such as euphoria, excessive goal seeking and self confidence. 
Interestingly, BAS sensitivity was also associated with an increase in positive affect and a decrease 
in negative affect, which too is consistent with the original BAS theory (56) where BAS is 
hypothesized to be associated with positive affect.  
Contrary to predictions, this study did not find that an increase in BAS sensitivity (as measured in 
the ESM diary), led to an increase in the likelihood of cannabis use. It may be that as individuals in 
the study had overall elevated levels of BAS (derived from the BAS total), consistent with other BD 
populations (19, 39) and the subtle fluctuations in BAS sensitivity (which the diary measures) were 
not strong enough predictors of whether an individual would use cannabis.  
Similarly, the study did not find support to suggest that higher levels of BAS total from the BIS/ BAS 
scale (20) would be associated with an increased likelihood of cannabis use. However, interestingly, 
and as predicted, those with higher scores on the BAS total experienced higher levels of manic 
symptoms, and also experienced higher levels of positive affect. This finding is similar to Meyer and 
Hoffman (57) who found that high self reported BAS predicted levels of positive affect and hypo-
manic symptoms in a sample of students over a 17-day diary study.    
Overall the findings from this study provide further evidence for an association between higher 
levels of BAS and manic symptoms and positive affect. The data from the study did not find an 
association between higher levels of BAS and cannabis use, on either the BAS total from the BIS/ 
BAS scale (20) or the BAS sensitivity from the ESM diary. Alloy et al (19) suggest that high BAS 
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activation should lead to increased substance abuse; therefore it may be that the BAS was not fully 
activated in participants in the current study. The mean BAS total was consistent with other BD 
samples, though this was at the lower end (19, 39). In addition, it may be that in comparison to 
other drugs of abuse, cannabis is not perceived as highly ‘rewarding’, being more easily accessible. 
A recent study (58) found that two thirds of 15 year olds reported that they knew where they could 
easily buy cannabis. Therefore individuals that use cannabis may not experience as heightened 
levels of BAS sensitivity in pursuit of cannabis compared to other drugs.  
 
LIMITATIONS 
Several limitations need to be taken into account in interpreting the results of the study. First, 
details of cannabis use were based on self-report. Cannabis use remains illegal in the United 
Kingdom, and this may have led to underestimations in reported use. Hair sample analysis may 
have offered a way to confirm usage (59). Additionally, whilst type of cannabis was reported and 
adjusted for in analyses, the individual potency of the drugs consumed was not controlled for. 
There are in excess of 100 different strengths of cannabis and research has revealed that on 
average, cannabis resin and herbal (grass) contains around 2-4 % THC, however  Sinsemillia (Skunk) 
contains around 12-18 % THC (60, 61). Data for cannabis use at each bleep was dichotomized into 
‘yes’ or ‘no’; future studies might attempt to  collect and report information regarding the amount 
of cannabis ingested and route of consumption at each beep. However the collecting of this 
additional information must be balanced against the further burden of data collection for the 
participant. 
 
This is the first time that ESM methodology has been used to examine changes in mood, symptoms 
and BAS sensitivity in a sample of individuals with BD. The items used on the scales for mania, 
depression and BAS sensitivity were formulated specifically for the study. However, to overcome 
any potential difficulties, items were chosen in accordance with guidelines for selection of ESM 
items (28). Items were also reviewed by a service user panel with BD who felt they accurately 
described their experience when manic and depressed. Additionally, scores on the BAS total from 
the BIS/BAS scale (20) were significantly associated with an increase on the BAS sensitivity scale in 
the ESM booklet (β = 0.11, 95% CI: 0.06 – 0.16, P = 0.000).  
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Cannabis is known to have an impact on cognition (e.g. 62, 63) and as suggested by Henquet et al 
(24) this may therefore have impacted on the ability to report information accurately in the diaries. 
However one of the main advantages of using ESM is the short space and time between an event 
occurring and the recall, which reduces memory bias (29). Additionally, a recent study (64) found 
cannabis use was associated with better neuro-cognitive functioning in participants with BD, 
particularly executive functioning. 
ESM can be a demanding methodology and requires sustained attention and motivation to fill out 
diary entries. This may deter some individuals, and thereby result in a selection bias. In addition, 
like other ESM studies (e.g. 65, 66) the sample size was relatively small hence the results for the 
study may not generalise to all individuals with co-occurring cannabis use and BD.  
Additionally, the majority of the sample was from a white British background and had a diagnosis of 
BD-I. It is therefore questionable how much the findings of this study may generalise to people from 
different ethnic minorities or other BD groups 
Finally, the inclusion of a control group may have provided insight into whether the findings from 
the study relate exclusively to those with a diagnosis of BD, compared to a non-clinical sample. 
CLINICAL IMPLICATIONS  
Overall results from the present study indicate that cannabis use can cause a range of psychological 
effects for individuals with BD, including an exacerbation of both manic and depressive symptoms. 
Co-occurring BD and substance abuse is highly prevalent (6, 67) and it is associated with worsened 
outcomes (5, 6). Therefore, as previously highlighted, this group of people represents an important 
group to study from both a clinical and public health perspective. However intervention research 
for BD and substance abuse is in its infancy (68, 69, 70, 71) and demonstrates a limited evidence 
base (68). The results from this study may help to inform future interventions.   
Clients often find it difficult to reduce their substance intake and the literature suggests that some 
individuals perceive cannabis as a useful coping strategy in the management of their BD symptoms. 
However results from this study may help to counter these positive expectations of their substance 
use. The findings suggest that cannabis is not being used to self medicate changes in symptoms, 
within the context of daily life, and in fact it may be further complicating affect states. Services and 
clinicians should be educated around the potential impact of using cannabis. They should be skilled 
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up to provide psycho-education to inform clients of the risks. Alongside this clinicians should be 
offering more helpful strategies to help clients cope with changes in BD symptoms, which may in 
turn increase an individual’s confidence to reduce their substance intake.   
 Similar to Henquet et al (24), the majority of participants in this study found the ESM diary a useful 
and reflective tool to monitor their mood and cannabis use. Therefore the methodology used here 
may also be of great clinical use. A number of participants reported that tracking patterns of mood 
and cannabis use led them to question their substance use and in some cases reduce intake. ESM 
could provide an invaluable therapeutic tool, particularly with clients who are ambivalent about 
changing their drug use habits. Tracking the course of symptoms and cannabis use may provide 
insight into unhelpful patterns of behaviour, which may contribute towards the maintenance of 
their difficulties.  
FUTURE RESEARCH 
BD is classified as a serious and enduring mental health difficulty and results from the present study 
indicate that the use of cannabis may in fact complicate the course of symptoms. Reasons for this 
may be due to the effects of THC in the central nervous system. Further research is indicated with 
individuals with BD to investigate the interaction between cannabinoids and dopamine. BD is 
characterised by difficulties with affect regulation, and whether the cannabinoid-dopamine 
interaction contributes towards the development of BD, or whether it further complicates affect 
states continues to be poorly understood. 
Further research is also need to see whether the results from this study would generalise to 
another sample of individuals with co-occurring BD and cannabis use. The inclusion of a control 
group would also provide further insight into whether the results relate exclusively to those with a 
diagnosis of BD.  
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OVERVIEW 
This section provides a critical reflection of the research process. It includes a rationale for the 
development of the literature review and the main empirical paper. This is followed by information 
regarding the study context and an examination of methodological and ethical issues which arose 
during the research process. Finally it discusses theoretical, clinical and future implications for 
research in this area.  
THE LITERATURE REVIEW 
Bipolar disorder (BD) is characterised by extreme shifts in mood from mania to depression. Whilst it 
is associated with achievement and artistic creativity (1), it can also be linked to a range of 
problems. These include difficulties with work performance (1, 2), higher rates of suicide in 
comparison to the general population (3) and elevated levels of substance use, particularly cannabis 
use (4, 5, 6).  
 
Strakowski and DelBello (5) provided a comprehensive review of studies exploring the co-occurring 
relationship between BD and substance use. However to the author’s knowledge there are no 
published review papers examining studies on the relationship between BD and cannabis use. A 
review of studies in this area was considered to be important since rates of cannabis use are 
elevated within the BD population (7) and are associated with a number of difficulties, including 
increased symptom severity (8) and non-medication compliance (8, 9).  
The production of the literature review highlighted a relative lack of research studies focusing 
specifically on BD and cannabis use, especially when compared to cannabis use and psychosis for 
which there is a large body of research available. There were a number of studies which explored 
the use of cannabis and mental health difficulties in general, however the author decided to only 
include studies where the sample included 50% or more individuals with BD. This was so the 
majority of the sample had a diagnosis of BD and the findings could be generalised to other 
individuals with the disorder.   
Following the exclusion of relevant papers, the final 13 included studies where the methodological 
quality varied. The studies reviewed employed a range of designs (e.g. longitudinal, cross-sectional, 
experimental, qualitative) and this led to both strengths and weaknesses for the paper. The use of 
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both quantitative and qualitative observations provided different ways of exploring the subject 
area, both complementing one another. However due to the range of methodologies used it was 
not possible to apply a common rating scale to critique the studies and was therefore difficult at 
times to draw comparisons between the studies. The papers were therefore critiqued on their 
individual quality and the findings were synthesised in relation to Strakowski and DelBello’s (5) 
hypotheses.  
The 13 studies reviewed provided new evidence with which to re-evaluate Strakowski and 
DelBello’s (5) 4 hypotheses in the context of cannabis use and BD (none of the 13 papers were 
included in their original review).  Similar to their findings for substance use in general, the 
literature review highlighted a number of factors which appear to contribute towards the co-
occurring relationship between BD and cannabis use.  
THE EMPIRICAL PAPER 
The review demonstrated that there are a number of factors which may contribute to the 
relationship between BD and cannabis use. The research paper was designed to investigate a 
number of these factors derived from the literature, which may explain the high co-occurrence of 
BD and cannabis use.  
This paper extended previous research by providing an in-depth investigation into the relationship 
between BD and cannabis use, over the course of daily life. There has been an increase in the 
number of researchers interested in investigating mental health difficulties within the realm of daily 
life (10, 11). This study utilized the Experience Sampling Methodology (ESM) to investigate 
associations between mood, BD symptoms, BAS sensitivity and cannabis use. The use of ESM 
provided many advantages when compared to traditional assessments - this will be discussed 
further in the next section. 
Overall the literature review and study contributes to a furthering of our understanding of what 
would seem to be a complex relationship between BD and cannabis use. A number of associations 
between cannabis use and aspects of BD were revealed which support the findings of other 
researchers. However the study did not find evidence to support the view that cannabis is used to 
self-medicate a change in symptoms over the course of daily life. The findings in relation to existing 
literature will be discussed further in the theoretical implications section. 
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THE STUDY CONTEXT – PARADES PROGRAMME 
The study was part of the PARADES programme (Spectrum Centre, Lancaster University) which is 
funded by the National Institute for Health Research (NIHR), and focuses on the development and 
implementation of psychological approaches to BD and co-morbid problems. The study sat within 
the substance misuse stream (1 of 2 studies investigating co-morbid BD and substance use) and 
being part of the PARADES programme offered a number of advantages which included; additional 
supervision from two of the grant holders (SJ: Professor of Clinical Psychology, Lancaster University 
and PARADES PI and RM: Professor of Psychiatry and Community Mental Health, University of 
Nottingham) and access to the service user panel of individuals with BD. Additionally, due to the 
large scale of the study for a clinical psychology doctoral thesis, a great advantage was having 
support from the Mental Health Research Network (MHRN) and from a research assistant (RA), in 
identifying and recruiting participants for the study.   
The RA and author worked closely together throughout the identification and recruitment stages of 
study, and this help and support was invaluable. In the identification stages, both parties attended 
team meetings individually and jointly. However due to time constraints for the author, the RA was 
able to attend more meetings and therefore was able to identify a larger number of participants for 
the study. The study also received support with the identification of participants (n=2) from clinical 
skills officers (CSO) who were part of the MHRN. During the recruitment stages the RA and author 
completed some joint participant visits (n=6) and the author completed a number alone (n=10).  
METHODOLOGICAL CONSIDERATIONS 
Experience sampling  methodology(ESM) 
An advantage of using ESM is the amount of rich and descriptive data it can provide. In the context 
of the study within this thesis, ESM allowed participants to report on their mood, BD symptoms and 
cannabis use   in the ‘moment’, and in their everyday settings. It thereby provided a high level of 
ecological validity. Previous studies investigating the relationship between BD and cannabis 
predominantly have used longitudinal study designs and participants have reported on their 
symptoms and cannabis use during follow-up assessments (12, 13). The information gathered in this 
manner may be open to recall biases and may not accurately depict the patterns of symptoms and 
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cannabis use. Stone et al (14) examined the correspondence between accounts of coping strategies 
following a stressor, using ESM diary methods versus a retrospective report produced 48 hours 
later. They found that there was poor correspondence between the two measures and the different 
representations suggest that information collected after a time period may be significantly different 
to information gathered just after an event.  
Limitations of ESM 
Whilst ESM offered a comprehensive, detailed investigation of the associations between aspects of 
BD and cannabis use, there were also a number of limitations which had to be taken into 
consideration. ESM could be perceived as a demanding methodology since completion of the diary 
entries requires sustained concentration, and can be time consuming for participants. ESM lends 
itself to being used by individuals who are motivated to complete the diary entries, and may 
therefore be open to a selection bias.  ESM may also deter individuals who are not comfortable 
with reading and writing.  
This study used the paper-based diary and watch method. An alternative approach would be to use 
personal digital assessments (PDAs). The use of PDAs provides superior control over diary entries as 
data can only be inputted at certain times, thereby preventing participants ‘backfilling’ entries at a 
later date. However certain individuals could find the technology daunting and difficult to use. 
Additionally, research suggests that using the paper-based diary and watch method yields similar 
results to PDAs (15). That being the case it was decided that the paper-based diary and watch 
method would be adequate for the study.  
There is also the potential that ESM could induce experiences for individuals (10), therefore a 
participants’ reaction to the study methods could change their experiences during the study. During 
the ‘debrief’ the participants were asked a number of questions about their experience of 
completing the research. A number of participants reported that the study had made them think 
more and focus on the way they were feeling, which will be discussed further in a following section. 
Additionally during the ESM week, participants were expected to act independently in accordance 
with the research protocol, without the presence of a researcher; therefore compliance was not 
always guaranteed (10). Nevertheless, to overcome some of the difficulties this may have 
presented, the watches were programmed to beep at according to a time schedule (which changed 
each day so the participants did not become accustomed to filling in their diaries at certain times 
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during the day). Participants were required to record the time after each diary entry. Once the 
study was completed, each diary entries were matched with the time schedule and any completed 
outside the 15 minute window were excluded from the analyses. Additionally a great deal of care 
was taken during the briefing stages of the study to ensure participants fully understood what was 
required  - this involved reading through all the questions in the diary and practicing an entry. 
Overall, compliance was good for the study. When the data in the diary was checked according to 
the time schedules, the author had to exclude very few entries (n=8). Additionally, there was a 
relatively low drop-out rate for the study. Two participants did not complete due to personal 
circumstance and 2 participants did not fill in enough diary entries during the week. 
Developing items for the ESM diary 
Developing items for the diary was a key part of the research process (see appendix G for booklet 
questions). Items for the study were formulated and chosen in accordance with past research (e.g. 
16, 17) and recent guidance (11). 
The mood items had been used in previous studies, investigating cannabis use and psychotic 
experiences (18). Given that factor analytic studies of these items had been done using data from 
people with schizophrenia diagnoses, a principal component analysis (see appendix I) was 
conducted for the present study and two distinct components were revealed. These were identified 
as a positive and a negative affect scale (See appendix). This, coupled with the cronbach’s alpha for 
each scale (positive α = 0.82, negative α =0.85) suggests that they are measuring separate 
constructs. Additionally, the high alphas’ indicate that the items in the scales are closely related.  
The mania and depression items were chosen by a team of researchers at the University of 
Manchester and from the PARADES programme (SJ, CB, ET). All of whom had considerable 
experience of working with people with BD and hence were familiar with the symptomatology. 
There were originally 8 items for BD; ‘full of energy’, ‘restless and fidgety’, ‘high’,  ‘full of good 
ideas’, ‘slowed down’, ‘low’, ‘bad about myself’ and  ‘fearful’. A principal component analysis (see 
appendix I) revealed two separate scales.  However ‘restless and fidgety’ (originally mania) loaded 
onto both factors and therefore this item was excluded from analyses. This left 3 items in the mania 
scale ‘full of energy’, ‘high’ and ‘full of good ideas’ and the remaining 4 items listed above for the 
depression scale.  The internal consistency for both scales was high, mania (α = 0.75) depression (α 
= 0.82), indicating that the items were closely related.  
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A correlation matrix (See appendix J) was computed to investigate the relationship between the positive 
affect, negative affect, mania and depressive scales. There was a strong correlation between the negative 
affect and depressive scales were highly associated (r = 0.82). This indicates that there may have been a 
high degree of overlap between the scales.  However during the main analyses the scales produced 
different results (e.g. cannabis use was significantly associated with depressive symptoms but not with 
negative affect). This provided some predictive validity to support the use of separate scales: and it 
suggests that they were measuring different emotional states. Items from the positive and negative affect 
scales were considered to reflect everyday mood fluctuations as expected within the ‘normal’ range.  The 
items formulated for the mania and depression scales were deemed to reflect symptoms specific to BD 
that would fluctuate over the course of daily life.  
 
Items for the BAS sensitivity scale were also developed specifically for the study. Three items were used 
to form the scale, ‘I want to try something new’, ‘Nothing can stand in my way’, ‘I’m craving excitement’. 
These were formulated using the same guidance as noted above (11) and were adapted from questions 
from the BIS/ BAS scale (19). Items were considered to measure levels of BAS sensitivity that would 
fluctuate over the course of daily life. The internal consistency for the scale was high (α = 0.76), again, 
indicating that the items were closely related. Additionally, as mentioned in the main paper, increases in 
scores on the BAS sensitivity (ESM diary) were associated with higher individual scores from the BIS/BAS 
scale (19).  
 
Service user involvement in the ESM diary 
 
A meeting was arranged with a group of service users who had a diagnosis of BD (n=4). Involving service 
users in the development of the study was seen as a key component and the author was keen to receive 
feedback on the wording of the questions in the diary. All members practised filling out the questions in 
the diary and they felt that the language reflected how they would describe their own behaviour and 
experiences.  
 
The study was also piloted with a single member of the group. Overall, feedback indicated that the 
participant had found the study interesting and enjoyable. They felt that the questions in the diary were 
appropriate and some reported that after filling out a diary entry, they recognised that their mood was 
becoming increasingly elevated and had found it helpful to recognise this change.  They noted that the 
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text message and phone call during the week helped with motivation and made them feel appreciated 
and recognised. This feedback emphasised the need to ensure that participants were contacted during 
the ESM week. Feedback from the services users was very positive and this gave the author confidence 
that the ESM diary had face validity in measuring individuals’ BD symptoms.  
 
BIS/BAS scale (19) 
The BIS/BAS scale (see appendix H) was originally developed by Carver and White (19) to assess 
individual differences in the sensitivity of the Behavioural Activation System (BAS) and the 
Behavioural Inhibition System (BIS). Their original factor analysis revealed 4 separate subscales. The 
BIS and three subscales which formed the BAS total (Drive, Fun Seeking, and Reward 
responsiveness).  
However more recent studies have conducted factor analyses and revealed two distinct factors, 
which correspond to the BIS and the BAS (20, 21). There is ongoing discussion over whether to use 
the BAS as three separate subscales; Ross et al (22) suggest that they should be considered as 
distinct constructs. However for the present study the BAS total was used as a number of other 
studies using a BD population have used the two factor structure and the BAS total was therefore 
comparable to these studies (e.g. 23, 24).  
It would have been interesting to run further analyses with the separate three subscales to see if 
any differences were found in relation to BD symptoms and cannabis use. However within the time 
constraints of the current thesis this was not possible.    
Recruitment 
The study recruited participants from a number of different sources (See figure 1) including 
community mental health teams (CMHT). During the recruitment stages there were a number of 
research studies recruiting individuals with BD and psychosis in the Greater Manchester area. This 
led to a few difficulties as some of the team managers who were approached were resistant to 
researchers attending team meetings, feeling that their teams had already been subject to a lot of 
research activity.  
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The author was mindful of interacting with team members in a sensitive manner and was acutely 
aware of the time pressures and demands facing care coordinators, particularly within the current 
NHS climate. Many of the teams that were approached were friendly and welcoming to research. 
However at a number of meetings, difficulties were experienced. In some cases team members 
appeared disinterested in the research and on a few occasions some were challenging about the 
study feeling that the ESM might be too demanding for their clients. This raised an important issue 
as it appeared that some members of the team were selecting clients whom they felt could take 
part in the research, rather than giving their clients the choice. This, of course could lead to a 
potential selection bias. This caused some frustration for the author as it was felt that some teams 
were putting up additional barriers to the research process and that all clients should have had 
been able to make their own decision about whether they wanted to be involved in the study (see 
appendix E for referrer information sheet).  
Figure 1:  Referrals/ final participants included in the study. 
 
 
 
 
 
 
 
 
 
 
 
*CMHT – Community Mental Health Teams 
**EIS – Early Intervention Services 
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Cannabis use 
Cannabis use and possession remains illegal in the United Kingdom and therefore the design of a 
study which involves individuals who use cannabis creates immediate difficulties. An ICM poll for 
BBC online (25) found that whilst 49 % of respondents supported the decriminalisation of cannabis, 
36 % were against it and a further 15 % were undecided. Therefore the use of cannabis remains a 
contentious issue within our society and from a researcher’s perspective it has to be treated 
sensitively.  
When introducing the study to potential referrers and participants, a particular emphasis was 
placed on confidentiality. Whilst the majority of team members were open and welcoming, there 
was a minority, as mentioned previously, who appeared to be unreceptive regarding the study. In 
the process of trying to understand this ambivalence, a number of potential reasons, in relation to 
cannabis use were formulated: 
-Some care coordinators felt that part of their role should be to support clients in reducing their 
drug-taking habits - admitting that one of their clients was using cannabis might look like a 
shortcoming.  
-They disapproved of their clients’ drug taking habits and did not want to expose them.  
-They were not aware of their clients’ drug taking habits.  
When presenting the study at team meetings, in an attempt to overcome any of these potential 
barriers, particular emphasis was placed upon discussion of research which reported on the high 
numbers of substance use within mental health populations. The aim was to ensure that team 
members felt comfortable talking about substance use. In some cases this did open up a range of 
discussions. Some teams were very receptive to the research study and felt that substance use by 
clients was a problem within their teams. They hoped that the research would provide more insight 
into why there were such high levels of use by individuals with mental health problems.  
Once referred into the study, participants seemed to be very open and honest regarding their drug 
use habits and happy to share information. Participants reported enjoying the chance to talk and 
reflect on their experience of taking drugs. This openness may have been facilitated by a non-
judgemental attitude from the author and the RA.   
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Assessment of cannabis use/ other substances 
The Structured Clinical Interview (SCID) based on the DSM-IV diagnostic criteria (26) was used to 
assess cannabis abuse and dependence. The SCID has been used in numerous research studies. 
There was a range of cannabis dependence within the sample (3 individuals currently met criteria 
for abuse and 12 for dependence). Similarly the number of times participants used cannabis over 
the ESM period ranged from 2 to 30, which was adjusted for in the analyses. However, overall, 
cannabis use was moderate for the sample. The mean number of ‘moments’ for the sample was 
15.4 (S.D 8.6) over the 6 day period.  
The type of cannabis used by the participants was recorded at each ‘moment’ (e.g. Resin, Grass or 
Skunk). To the author’s knowledge this is one of the first studies to adjust for this information in the 
analyses when investigating co-occurring BD and cannabis use. Previous studies have dichotomised 
cannabis use into ‘yes’ or ‘no’ (e.g. 12). However, there are many different types of cannabis which 
contain various concentrations of ∆9-tetrahydrocannabinol (THC) and cannabinol (CBD: 27, 28). 
These cannabinoids are thought to be responsible for the range of psychological and physiological 
effects produced by cannabis. 
Type of cannabis was not significantly associated with a change in mood, symptoms or cannabis 
use. Previous research had indicated that cannabis containing higher levels of THC (e.g. skunk) could 
cause more adverse psychological effects (29), therefore it was expected that individuals using the 
higher strengths may experience more mood/ symptom changes. However whilst the type of 
cannabis was recorded, the amount and frequency of use at each beep was not. Therefore some 
individuals may have been using a larger quantity of the lower strength cannabis between the 
beeps, as compared to those using the higher strength cannabis. Future studies should aim to 
collect information on the amount, frequency and the route of consumption of cannabis at each 
beep, as this would provide a more accurate measure of cannabis use.  
The effect of other substances was also adjusted for in the analyses (alcohol and use of other drugs 
at the same beep). However, similarly to cannabis use, the amount and frequency of the alcohol/ 
other drug use was not recorded between beeps.  Alcohol at the same beep was associated with 
subsequent increases in positive affect and manic symptoms; therefore it was adjusted for in the 
analyses that investigated the effects of cannabis use on mood and symptoms. Other drug use was 
not associated with changes in mood or symptoms. There was overall low usage of alcohol (mean 
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number of moments = 3.5) and other drugs (mean number of moments = 0.9) over the 6 day study 
period.  
The participant sample 
The majority of the participant sample had a diagnosis of BD-I and were from a white British 
background. Research has highlighted differences between BD populations, for example Kupka et al 
(30) found that patients with rapid cycling BD differed significantly from those without rapid cycling 
on a number of variables such as: number of lifetime manic/ depressive episodes, history of drug 
abuse, history of childhood sexual/physical abuse. It may not therefore be possible to generalise 
results from this study to other BD populations. 
 Previous research has reported high incidence rates of mania within ethnic minority communities 
in the UK, especially those from African-Caribbean and African ethnicity (31, 32).  Research has 
shown that there are major differences in the way individuals from different ethnic minorities 
access mental health services (33). Therefore the under-representation of people from different 
backgrounds in the study may reflect this. Additionally, because only 3 people with non-white 
British backgrounds were included in the study, the results are not generalisable to individuals from 
different ethnic backgrounds. 
 The sample size for the study was relatively low. This was nevertheless enough to detect effects 
(due to the multilevel nature of ESM data). However it is questionable how much the findings 
would relate to other individuals with co-occurring BD and cannabis use.  
The inclusion of a control group may have provided insight into whether the associations revealed 
in the study relate exclusively to individuals with BD or whether they relate to non-clinical samples. 
Henquet et al (18) found significant differences between their patient sample and control group. 
Daily cannabis use predicted subsequent increases in positive affect and increased levels of 
hallucinatory experiences in the patient only group.   
Statistical analyses 
The statistical analyses were conducted by the author. Supervision for the multi-level modelling 
techniques was provided by a research methods fellow (LC). 
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Henquet et al (18) used ESM to provide insight into the complicated dynamics of cannabis use and 
its effect on mood and psychotic experiences. In the main, the present study replicated the 
statistical analytic strategy that Henquet et al (18) used in their study. However in the Henquet et al 
(18) paper when they investigated the self-medication effects (mood/ symptom change predicting 
cannabis use), they additionally adjusted for cannabis use at the previous beep, due to the fact that 
cannabis use at the previous beep was strongly associated with cannabis at the current beep. 
Likewise, when investigating the effects of cannabis on mood / symptoms, they adjusted for mood 
and symptoms at the previous beep. This was based on the fact that mood/ symptoms at the 
previous beep were strongly associated with mood/ symptoms at the current beep.  
However, after seeking statistical advice, it was advised that the inclusion of previous beep values 
(e.g. cannabis/ mood/ symptoms) of the dependent variable as a covariate in a longitudinal 
multilevel model can lead to false correlations due to mathematical linkage.  Previous beep values 
of the dependent variable estimate the random effect term of the current dependent variable. 
Therefore this effect will be larger, particularly if the cluster size is small and the clustering effect is 
large. Therefore it was decided not to include previous beep variables in any of the models as the 
inclusion may have led to the effect sizes been underestimated.  
Participant feedback on the study  
Feedback regarding the study process was gathered at the end during the debrief session. The 
majority of the sample reported they had enjoyed the study. Twenty of the participants reported 
that it had been a typical week in relation to their symptoms - this was an important finding as it 
increased the validity of the reported associations. The majority of the sample (21 out of 23) 
reported that filling the diaries out had not affected their cannabis use. Two individuals reported 
that filling out the diary had led to a change in their cannabis use. These 2 individuals found that 
they had become more aware of the effect of cannabis on their mood and this had motivated them 
to want to reduce their usage.  
Eight of the participants felt that the study had influenced their mood. The reasons for this included 
reflecting and focusing more on their mood - the diary made them think and concentrate more on 
how they felt. A number of participants reported that they had used more cannabis after the beeps 
had finished for the day.  A visual scan of the data confirmed that the majority of missing beeps 
were at the beginning of the day. This would need to be taken into account when designing studies 
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with similar populations and possibly the time schedule would need to be altered to fit more 
accurately with lifestyle.  
Receiving the feedback from the participants at the end of the study was a very important part of 
the process. The finding that the majority of individuals had enjoyed participating in the study was 
pleasing for the author. The feedback regarding timings was useful and should be taken into 
consideration in the design of future studies in this area.   
ETHICAL CONSIDERATIONS 
 
Ethical approval was sought and granted from the National Research Ethics Service committee 
(NHS: see appendix B for the ethics approval letter and appendix C for research governance letter – 
an example from one of the trusts). A number of ethical issues had to be taken into consideration 
when designing and conducting the study. 
Consent 
All participants were given an information sheet (see appendix D) with details of the study, prior to 
signing the consent sheet. This gave the participant and author time to discuss the objectives of the 
study and also gave the participants an explanation of what the process would involve. Both parties 
signed two copies of the consent sheet (see appendix F), one for the participant and one for the 
author, which were kept in a locked filing cabinet. Participants were informed that they were free 
to withdraw from the study at any point, without giving any reason and that they had the option for 
their data to be destroyed.   
Confidentiality 
All information gathered from participants during the research study was kept confidential, 
including information about their substance use. Any identifiable information was kept separately 
from study measures in a locked filing cabinet. At the first meeting participants were informed that 
everything they discussed during the research process would be kept confidential. However they 
were informed that if the author was concerned that the participant might be a risk to themselves 
or others, then this information would have to be shared with another party (though they would 
always aim to discuss this with the participant first).   
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Individuals with both BD and substance use do present as an increased ‘risky’ population, due to the 
nature of the conditions. There are reported higher rates of suicide in comparison to the general 
population (3). Therefore monitoring the clients risk to self was an important part of the research 
process. On one occasion, during a second visit, the author was concerned about a participant’s 
welfare as there had been an apparent deterioration in mood between the two visits. Permission 
was granted from the participant to contact the named care coordinator.  
 
 STUDY IMPLICATIONS 
Theoretical and future implications 
The findings from the study might be discussed in relation to the stress-vulnerability model which 
was first proposed by Zubin and Spring (34). This model was not discussed in the main paper; this 
was due to the format of the ‘paper-based’ thesis which does not permit space to fully elaborate on 
the theoretical implications. The model proposes an aetiological mechanism for mental health 
disorders as well as an explanation for relapse; and its basic premise suggests that some people 
(those with an underlying predisposition) are vulnerable to developing /relapsing into mental health 
difficulties if they are exposed to enough stressors. Stress may come in many forms and can include, 
biological, developmental, psychological, environmental and socio-cultural and different people are 
thought to be vulnerable to different stressors. Therefore, for some individuals in the study, 
cannabis use may have been a ‘stressor’ and contributed to the exacerbation of their BD, however 
for others, different factors may have contributed towards their mental health difficulties. In the 
context of every day life, each individual’s vulnerability and sensitivity to the effects of cannabis use 
may be different, which may explain why a range of effects in the study were reported. This will be 
explored further in the following section.  
Effects of Cannabis 
The findings from the empirical paper suggest that within the context of daily life, cannabis use is 
associated with an increase positive affect and manic and depressive symptoms for individuals with 
BD. However due to the nature of the study design, this finding is limited to the associations 
between cannabis use at the current /previous beep and these variables, therefore cannot indicate 
causation. The results suggest that the effects of cannabis on positive and depressive symptoms 
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were experienced only in the short term as cannabis use at the previous beep did not predict a 
significant increase in mood or symptoms at subsequent time points. 
These findings are consistent with current literature that suggests that cannabis use is associated 
with manic symptoms (12, 35, 36), with depressive symptoms (37, 38) and positive affect (18). The 
findings are also consistent with research which has suggested that cannabis can cause bidirectional 
effects (39, 40, 41), causing effects such as euphoria and dysphoria. Barkus and Lewis (42) found 
that individuals scoring higher on Schizotypal traits were more likely to experience both psychosis-
like experiences (negative) and more pleasurable experiences (positive) after smoking cannabis.  
A study with ‘healthy’ participants, under placebo-controlled laboratory conditions found that THC 
(one of the key constituents that are present in cannabis) was reported to produce relaxation and 
there was a decrease in subjective ratings of depression (40). The current study found that cannabis 
was associated with an increase in depressive symptoms.  However Ashton et al (40) utilised a non-
clinical sample which may explain why cannabis was associated with different psychological effects 
from those in this study. Henquet et al (18) found that cannabis use was significantly associated 
with subsequent increases in hallucinations in their patient sample compared to their non-clinical 
student sample. 
As mentioned previously, it has been suggested that the main psychological and physiological 
effects of cannabis are due to its key constituents, THC and CBD. Recent experimental work with 
‘healthy individuals’ has found that intravenous infusions of THC can produce mild to transient 
psychotic like symptoms, anxiety and feelings of detachment (43). Once ingested, THC mimics the 
actions of natural cannabinoids and binds itself to cannabinoid (CB1 and CB2) receptors. Neuro-
anatomical findings suggest CB1 modulates and interacts with the function of dopamine (44). The 
repeated production of cannabinoids may lead to a permanent change in dopamine levels (45, 46).  
A recent study found that THC did induce dopamine release in the human striatum in a sample of 
‘healthy’ participants (47). However, Stokes et al (48) found that THC did not produce significant 
dopamine releases in the striatum. Henquet et al (18) suggest that the differing findings may be 
because individuals differ in their sensitivity to THC. The effects of cannabis are known to differ 
depending on dose, personality and degree of tolerance (39, 40, 41).  
There is limited evidence that suggests that (mesolimbic) dopaminergic hyperactivity may 
contribute towards psychosis/ and mania (49), therefore it has been suggested that dopaminergic 
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hyperactivity may underlie the link between cannabis and BD (36, 50). Compared to BD, the 
relationship between THC and vulnerability to developing psychosis has been subject to far more 
investigation. A number of factors have been identified which in combination with THC, increase 
the likelihood of causing psychosis. These include pre-existing psychotic symptoms (51) and 
exposure to childhood trauma (52, 53). Further research is clearly indicated firstly to investigate the 
interaction between cannabis and its effect on dopamine in the brain and secondly to investigate 
which factors may make individuals with BD more vulnerable to the effects of cannabis use.  
Self-medication 
The study did not find evidence to support the use of cannabis to self-medicate fluctuations in 
symptoms over the course of daily life. However, as discussed in the main paper, this may be 
because cannabis is used further down the chain of events, when symptoms escalate or become 
more pronounced. As discussed previously this is the first known study to investigate the 
relationship between BD and cannabis use in daily life. Therefore it may be that cannabis is used 
only when there is a dramatic change in symptoms, which potentially may not be measurable using 
the ESM diary (since it is designed to measure fluctuations in symptoms which occur in the 
moment). Previous self-report studies have found that cannabis is used to self medicate symptoms 
of both mania and depression (54, 55, 56). However these reports are completed retrospectively 
and may be open to recall bias.  
Further research in this area should focus on at what stage in the course of BD individuals use 
cannabis as a form of self-medication, and also what impact self-medication has on an individual’s 
symptom levels.  It may be that individuals with co-occurring BD and cannabis use find themselves 
trapped in a vicious cycle of mood instability and cannabis use. An individual may experience subtle 
fluctuations in mood and continue with their cannabis use as normal. However these symptoms 
may begin to escalate and once they have become more noticeable and pronounced, cannabis may 
be used as a form of self medication. This may be perceived as helpful (since symptoms are 
alleviated) and in consequence increasing the likelihood of cannabis being used again the next time 
a significant change in mood is experienced.   
See figure 2 below: 
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BAS theory 
The Behavioural Inhibition System (BIS: 19) and the BAS (57) are proposed to be the two major 
motivational systems. It is hypothesised that the BAS is related to goal attainment behaviour, 
reward seeking and positive affect (e.g. 57). According to Depue and colleagues (58, 59) the BAS 
regulates behaviours and moods typically observed in mania and depression. Therefore a 
dysregulated BAS may lead to a vulnerability to BD and those who are vulnerable may react strongly 
when faced with rewarding stimuli.   
Findings from the study revealed an association between both the BAS sensitivity scores from the 
ESM diary and the BAS total scores from the BIS/BAS scale (19) and an increase in manic symptoms. 
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This association provides further support for the BAS hypersensitivity theory of BD (58, 59) which 
suggests that a sensitised BAS is reflected in (hypo) manic symptoms such as euphoria and 
excessive goal seeking. A number of other studies have revealed an association between individuals 
with BD spectrum disorders reporting elevated self-report scores of BAS sensitivity and exhibiting 
(hypo) manic symptoms (e.g. 24, 60).  
Individuals with substance abuse also exhibit higher self-reported BAS sensitivity (61, 62), leading 
several theorists (63, 64) to hypothesise that increased levels of reward sensitivities or drive (i.e. 
BAS) may also contribute towards the development and maintenance of substance abuse problems. 
In a longitudinal study comparing BD spectrum and ‘healthy’ individuals, Alloy et al (60) found that 
higher BAS sensitivity predicted BD status and increased substance use problems.  The authors 
concluded that higher BAS sensitivity may represent a shared personality vulnerability for both BD 
and substance use disorders, which may partially explain their co-occurrence 
The findings from the study did not reveal a significant association between higher levels of BAS 
(measured by BAS sensitivity scale from ESM diary and BAS total from BIS/BAS scale) and cannabis 
use. As noted in the main paper it may be that the BAS was not fully activated in participants in the 
current study - the mean BAS total was at the lower end, compared to other BD samples (24, 60). 
Furthermore, as also noted in the main paper, it could be due to an individual not perceiving 
cannabis as ‘highly’ rewarding compared to other drugs – therefore they might not experience such 
heightened levels of BAS activity in pursuit of cannabis.  
A further understanding of these personality vulnerabilities does warrant further attention as they 
may provide opportunities for future intervention. One way of further investigating the role of the 
BAS in BD and cannabis users would be to compare scores on the BIS/BAS (19) and ESM data for 
‘healthy’ individuals who use cannabis, individuals with BD and individuals with co-occurring BD and 
cannabis use. This may provide some insight into which individuals are more likely to experience 
increases in mood/ symptoms/BAS sensitivity as a result of cannabis use and visa versa.  
 
Implication of the study for clinical practice 
As previously discussed co-occurring BD and substance abuse is highly prevalent (4, 5, 6) and it is 
associated with worsened outcomes (1, 2, 3).  However intervention research for this particular 
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group of people is still in its infancy (67, 68, 69, 70). The data from the main study may help inform 
future interventions.  
Overall the findings indicate that cannabis use can lead to a range of psychological effects for 
individuals with BD, including an exacerbation of both manic and depressive symptoms. 
Researchers have reported on the potential therapeutic role for cannabis in the management of BD, 
due to the pharmacological properties contained in THC and CBD (65). Those authors report that 
cannabis may exert a number of effects such as sedative, hypnotic, anxiolytic, anti-depressant and 
anti-psychotic.  It therefore appears that cannabis may be perceived as useful for some individuals 
with BD as Ashton et al (65) and the self-report literature suggests that people often use cannabis 
as a coping strategy in the management of their BD (54, 55, 56). However results from the study 
indicate that it may further complicate mood for some individuals with BD. Individual differences in 
sensitivity to cannabis may explain the complexity of this relationship and as discussed previously 
further research in this area is indicated. 
The results from the study may help to counter some individual’s positive expectations of their 
cannabis use.  Clients often find it difficult to reduce their substance intake and one of the reasons 
for this may be due to the perception that cannabis is a useful coping strategy. Firstly services and 
clinicians should be educated around both the potential impact of using cannabis. They should be 
skilled up to provide psycho-education to inform clients of the risks. Subsequently the development 
of behavioural experiments may be one useful way to target client’s beliefs about their cannabis 
use. This could be achieved by asking clients to make predictions about their mood/ symptoms 
following cannabis use and then use self-monitoring to track their actual experiences.  Alongside 
this clinicians should be offering more helpful strategies to cope with BD symptoms, which may in 
turn increase an individual’s confidence to reduce their substance intake.   
As discussed in the main paper, the use of ESM may provide an invaluable therapeutic tool. When 
participants were asked about their experience of taking part in the study, 8 of the sample reported 
that using the diaries had increased their awareness of their symptoms and cannabis use. 
Additionally, two participants made an association between changes in mood and their cannabis 
use and this realisation had initiated a change in their cannabis use. The service user that piloted 
the study reported that on one occasion he had become aware that his mood was becoming high, 
and therefore was able to put some coping strategies in place to prevent further escalation.   
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The feasibility of using of PDAs as a self-help tool for individuals with BD warrants further 
investigation. The use of technology is becoming gradually more prevalent in psychological research 
and clinical practice (66). PDAs could be programmed to beep throughout the day and upon hearing 
the beep participants could be instructed to respond to brief questions. If participants scored above 
a certain cut-off point, they could be offered an intervention (e.g. a coping strategy specific to their 
symptoms). The use of PDAs in the form of ‘relapse prevention’ could provide an invaluable 
therapeutic tool for individuals who find it difficult to access psychological services.    
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APPENDIX D     Experiences of Substance Use in                
Bipolar Disorder 
Participant Information Sheet 
 
Bipolar Disorder and Substance Use: Service User Experiences 
We would like to invite you to take part in a service user defined research study. Before you 
decide whether you would like to take part, it is important that you understand why this 
research is being done and what it will involve. Please take the time to read the following 
information carefully and discuss it with others if you wish. Please ask us if there is 
anything that is unclear or that you would like more information about. Take time to decide 
whether or not you wish to take part.  
What is the research project about?  
This research aims to find out more about peoples’ experiences of substance use in bipolar 
disorder, what positive and negative effects substances may have on the course of the 
illness and if and how substance use is related to Bipolar symptoms. 
The research is related to another study we conducted last year using Q methodology 
involving participants with Bipolar Disorder who regularly use alcohol and/or cannabis 
(sorting cards relating to reasons for substance use). This study has now finished. 
Who is organising the research?  
This project is being organised by a team of researchers, academics and health 
professionals from Manchester Mental Health and Social Care Trust, the Universities of 
Manchester and Lancaster and a Service User Reference Group comprising of service users 
from across the North West.  
The research will focus specifically on Cannabis use in Bipolar Disorder and will ask that 
participants wear a watch for 6 days which will beep at random times throughout the day 
to prompt completion of a brief diary. 
Who will be taking part?  
We will recruit up to 40 participants with Bipolar Disorder who regularly use Cannabis. 
The criteria for cannabis use is: use at least two times per week in at least half the weeks 
in the 3 months prior to assessment. 
Participants will be recruited from the North West and East Midlands. Participants’ minimum 
age will be 18.  
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Why have I been asked to take part?   
Sharing your experiences with us will help to increase our understanding of substance use 
in bipolar disorder. We think that you could make a valuable contribution to this research 
project   
Do I have to take part?  
It is completely up to you to decide whether or not you would like to take part. If you do 
decide to take part you will be given a copy of this information sheet and be asked to sign a 
consent form. If you do decide to take part but change your mind later you are free to 
withdraw at any time and do not need to give us a reason. If you do decide not to take 
part, or to withdraw at any time, we will not use any of the data we may already have 
collected from you. Decision to withdraw will not affect the standard of care you receive.  
What will taking part involve for me?  
If you do decide to take part, a research assistant will arrange a time to come and meet 
you, either at home or at another place where you feel comfortable. We will ask you some 
questions first about your mood and substance use, just to confirm that you meet the 
criteria for the study. We will also take some details about prescribed medications you 
currently take. These questions will take 60-90 minutes. 
We will then arrange another appointment to conduct the study.  
The study uses a method called Experience Sampling. This is a structured diary method 
where you will wear a watch for 6 days which beeps randomly at 10 different times 
throughout the day. Immediately following the beep you will be asked to fill out a booklet 
containing questions on your current situation, mood, bipolar symptoms and cannabis use. 
You can continue with your usual routine whilst wearing the watch. 
Appointments will be audio taped. This is so that researchers can reflect on what is 
discussed and accurately record any extra details you provide. 
Is the study confidential? 
All the information that you give will be strictly confidential. Any data taken from you during 
the study will be held by the immediate research team. The research team may access your 
medical notes to help us clarify diagnostic issues however this is optional so you can refuse 
this access if you wish. 
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Data and material may be looked at by relevant individuals from the University of 
Manchester, regulatory authorities or the NHS Trust, for monitoring and auditing purposes. 
In these situations, strict confidentiality will be maintained. 
The information (data) collected will be anonymised, any tapes will be destroyed at the end 
of the study and any direct quotes used in the write up of the study will be done so in such 
a way as not to identify individuals.  
If at any point during your involvement with the study, the research team are concerned 
for you in any way, they may wish to contact someone involved in your care. If this is the 
case, they will speak to you about it first and explain what they plan to do.  
What are the advantages and disadvantages of taking part?  
The study will give you a chance to reflect on your experiences of substance use in bipolar 
disorder. We hope that your experiences will help to inform the development of an 
intervention specifically for people who use substances in bipolar disorder, which will 
hopefully influence the practice of mental health professionals in delivering treatment and 
interventions to yourself and other service users.  
Participants who complete the study will receive £10 towards expenses. This will be given 
at the end of the 6 day period, once booklets are completed and watches are returned.   
It is possible that talking about your personal experiences may result in some distress. The 
people interviewing you will be sensitive to this. You will have the opportunity to discuss 
any concerns at the end of the interview and you are free to withdraw from the process at 
any point. We will check if there are any concerns you wish to raise and, if necessary, you 
will be able to talk to one of the clinical psychologists on the research team.  
What do I do if something goes wrong? 
If you are harmed by taking part in this research project, there are no special compensation 
arrangements. If you are harmed due to someone’s negligence, then you may have 
grounds for legal action but you may have to pay for it. Regardless of this, if you wish to 
complain, or have any concerns about any aspect of the way you have been approached or 
treated during the course of this study, then in the first instance please contact: 
Professor Christine Barrowclough, Professor of Clinical Psychology, The University of 
Manchester, Manchester, M13 9PL 
 Telephone: 0161 2758485 Email: Christine.Barrowclough@manchester.ac.uk or 
Professor Steven Jones, Professor of Psychology and Clinical Psychologist, Spectrum Centre 
for Mental Health Research, Lancaster University, Lancaster, LA1 4WY. 
Telephone: 01524 593756   Email: s.jones7@lancaster.ac.uk 
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What will happen to the results of the research? 
If you participate in the above study you will be informed of the results. The findings will 
also be presented to a range of mental health professionals and service users with the aim 
of increasing the understanding substance use in bipolar disorder. It is hoped that the 
findings will also help to improve services and validate the experiences of other service 
users. The findings will be published in mental health journals and other publications with 
the aim of reaching a range of mental health professionals and service users.  
The findings will be used to inform subsequent phases of the PARADES programme: a 
treatment development phase involving consultation with service users and health 
professionals to develop an intervention for substance use in bipolar disorder. What we 
learn from this study will be key in helping us to do this.  
If you want any further information or have any questions, please contact the research 
assistants on this project: 
 
Nancy Black – Research Assistant 
nancy.black@nhs.net or 
 
Lizzie Tyler – Trainee Clinical Psychologist 
Elizabeth.Tyler@postgrad.manchester.ac.uk 
 
Telephone: 0161 275 8498 
/07553 388373 
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APPENDIX E 
 
Experiences of Substance Use in Bipolar Disorder 
Bipolar Disorder and Substance Use: Service User Experiences 
Referrer Information Sheet 
Who we are 
We are a team of researchers based in the North West. The Primary Investigator of the PARADES 
programme is Professor Steven Jones based at the Spectrum Centre for Mental Health Research at 
Lancaster University and the Chief Investigator for the Substance Misuse in Bipolar Disorder stream 
is Professor Christine Barrowclough based at the University of Manchester. Dr Lisa Riste is the 
Programme Manager, and there are two researchers working on this study: Nancy Black (Research 
Assistant) and Lizzie Tyler (Trainee Clinical Psychologist).  They will be assisted with recruitment by 
members of the Mental Health Research Network team. 
Study aims 
This study endeavours to understand more about the experiences of Substance Use for patients with 
Bipolar Disorder. This phase of the project will have 2 parts:  
Part 1 employs Q methodology which involves participants sorting through a deck of cards which 
have individual statements written on them and placing the cards in their chosen order onto a 
response grid which identifies on a continuum which of the statements apply to them and which do 
not. The order in which the cards are placed will be recorded and later compared with other people’s 
answers to investigate whether any themes or patterns emerge. There are 2 separate decks of cards 
to sort through – the first will describe immediate experiences of substance use in Bipolar Disorder 
and the second will describe delayed experiences of substance use in bipolar disorder. We will ask 
participants to complete both card sorts.  
Part 2 uses a method called Experience Sampling. This is a structured diary method where 
participants will wear a watch for 6 days which will beep 10 times throughout the day. Immediately 
following the beep participants will be asked to fill out a booklet containing questions about their 
current situation, mood, bipolar symptoms and cannabis use. 
Participants who use cannabis regularly will have the option of being involved in both parts, but they 
can decide to take part in only 1 if they wish. 
Those who use alcohol will be suitable for part 1. 
The results of both studies will then be used to inform subsequent phases of the project, a treatment 
development phase which will involve consultation with service users and health professionals to 
develop an intervention specifically for substance use in bipolar disorder. This will then be trialled in 
Phase 3 of the project with participants who experience substance use in bipolar disorder and we will 
measure this in terms of effectiveness and feasibility. We will be recruiting for phases 2 and 3 at a 
later date. 
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Rationale 
There is a high level of substance use (SU) in individuals with Bipolar Disorder (BD). Some studies 
have reported levels up to 60%; this level is higher than any other Axis 1 psychiatric disorder. Many 
studies have shown that outcomes of having both disorders concurrently can be far worse than 
managing one of these disorders alone, for example with higher levels of treatment non-compliance, 
higher rates of suicide and increased periods of depression.  
Despite the growing concern for patients living with dual diagnosis, there has been very little 
research into specific treatments for this co morbidity. Some trials testing psychological treatments 
for BD and SUD have shown some improvements in Substance Use but not necessarily in symptoms 
of BD. Research to date suggests that people with Bipolar Disorder use substances for different 
reasons – some give the same reasons as people without a co-morbid mental health problem; but 
some suggest that they use to help treat symptoms of BD.  
The planned studies aim to explore the relationships between Bipolar Disorder and Substance use 
more closely, asking participants with both diagnoses how it really is for them. 
 
Start date  
We will be recruiting from March 2010. Recruitment will continue through until July 2011. 
 
Criteria 
 
We are looking for approx 40 people to take part in each study. Participants will meet the following 
criteria: 
 
Study 1: 
• Have a diagnosis of Bipolar disorder I or II 
• Age 18+ 
• Alcohol use per week exceeding 28 units for males/ 21 units for females 
• OR use of Cannabis at least two times per week 
 
Study 2: 
 
• Have a diagnosis of Bipolar disorder I or II 
• Age 18+ 
• Use of Cannabis at least two times per week 
 
 
Get involved! 
We would like you to consider anyone you are currently working with who may have bipolar 
disorder and regularly use cannabis or alcohol, and tell them about the research. Then if they 
are interested, ask them if it would be ok for one of us to contact them with more information. 
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We will provide extra details and answer any questions people may have. If they wish to take 
part, we will gain their written consent. This is an exciting time for service users to get involved 
in research into their own health problems and to be involved in change and development.  
 
 
Any questions, queries or referrals, please contact us any time on: 
Nancy Black (nancy.black@nhs.net) or  
Lizzie Tyler (Elizabeth.tyler@postgrad.manchester.ac.uk)  
Or Telephone: 0161 275 8498 
Mobile: 07553 388 373 
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APPENDIX F                      CONSENT FORM – Part 2 
 
Bipolar Disorder and Substance Use: Service User Experiences 
Part 2 (Bipolar Disorder and the use of Cannabis: An Experience Sampling 
Study) 
REC ref:      
Name of Researcher:      
Name of Participant:      
 
Participant Number   
 
 
1. I confirm that I have read and understand the information sheet version 
number …V4…. dated …13/06/10……for the above study and have had the 
opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, and without my medical care or legal 
rights being affected.  
 
3. I give my consent for my appointments with the research team to be audio-
taped so that the researchers can reflect on what was discussed and record 
accurately any extra information I provide. 
 
4. I give my consent for the research team to access my medical records should 
they need to clarify diagnostic information or update risk assessments. 
 
5. I understand that any data collected during the study may be looked at by 
individuals from regulatory authorities or from the NHS trust, where it is 
relevant to my taking part in this research. I give permission for these 
individuals to have access to my records and to collect, store, analyse and 
publish information obtained from my participation in this study. I understand 
that my personal details will be kept confidential. 
 
6. I agree to my GP (and care co-ordinator where appropriate) being informed of 
my participation in this study and being informed should the researchers have 
concerns about my mental health while I’m in the study. 
 
7. Please indicate if you would like to be informed of the results. 
 
8. I agree to take part in the above study. 
 
9. I give permission for my direct quotations to be recorded and used if required in             
published format, and understand that this information will be kept anonymous. 
 
10.  I agree for my details to be available to other researchers within the PARADES  
         Programme and for them to contact me should I be considered appropriate for  
   related studies. 
 
______________________ ______________     ____________________ 
Name of Participant  Date          Signature 
 
________________________ ______________     ____________________ 
Name of Person taking consent Date          Signature 
(If different from Principal Investigator) 
 
Please initial box
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APPENDIX G 
 
 
What was I thinking (just before the beep went off)……………………………………… 
…………………………………………………………………………………………………. 
       This thought was…              Not                                Moderately                                Very
§ pleasant 1 2 3 4 5 6 
§ clear 1 2 3 4 5 6 
§ normal 1 2 3 4 5 6 
  
                        I have trouble concentrating 1 2 3 4 5 6 
  Please describe your mood just before the beep went off: 
                  I feel... Not   Moderately                           Very
§ cheerful 1 2 3 4 5 6 
§ excited 1 2 3 4 5 6 
§ lonely 1 2 3 4 5 6 
 
§ relaxed 1 2 3 4 5 6 
§ anxious 1 2 3 4 5 6 
§ satisfied 1 2 3 4 5 6 
 
§ Irritated 1 2 3 4 5 6 
§ sad     1 2 3 4 5 6 
§ guilty  1 2 3 4 5 6 
                        Overall, I’m feeling happy 1 2 3 4 5 6 
                   Right now.....   Not   Moderately   
§ I like myself   1        2 3 4 5 6 
§ I am ashamed of myself            1       2 3 4 5 6 
§ I am a failure   1        2 3 4 5 6 
§ I am a good person   1        2 3 4 5 6 
                   Right now I am...   Not   Moderately   
§ full of energy 1 2 3 4 5 6 
§ restless and fidgety 1 2 3 4 5 6 
§ high 1 2 3 4 5 6 
§ full of good ideas 1 2 3 4 5 6 
 
                  Right now I feel… 
§ slowed down 1 2 3 4 5 6 
§ low 1 2 3 4 5 6 
§ bad about myself 1 2 3 4 5 6 
§ fearful 1 2 3 4 5 6 
                 Right now…  
§ I am suspicious 1 2 3 4 5 6 
§ I hear voices 1 2 3 4 5        6 
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   Right now… 
 
§    I want to try something new                     12 3 4 5 6 7 
§    Nothing can stand in my way                   12 3 4 5 6 7 
§    I’m craving excitement                             12 3 4 5 6 7 
               Where am I? …………………………………………………………………………………………………… 
               Am I alone?  Yes / No  
     If not, with whom? ……...…..……………………………………………………………………………….. 
               How many men?.............women?................children?............................ 
 With these people, I feel…..    
Not          Moderate                      Very  
 
   Comfortable              1 2 3 4 5 6 7 
   Threatened     1 2 3 4 5 6 7 
   Accepted     1 2 3 4 5 6 7 
  Frightened     1 2 3 4 5 6 7 
 What was I doing (just before the beep went off)…………………………………………... 
…………………………………………………………………………………………………… 
        Not      Moderate          Very 
  I would prefer to be doing something else 1 2 3 4 5 6 7 
  I’m active     1 2 3 4 5 6 7 
  I takes a lot of effort    1 2 3 4 5 6 7 
  I am skilled to do it    1 2 3 4 5 6 7 
  I was challenged by it    1 2 3 4 5 6 7 
 
 Since the last beep, the most important event that happened to me was: ……………...... 
……………………..………………………………………………………………………………. 
  
                                                          Very Unpleasant        Moderate                 Very Pleasant 
              This was:                                              -3 -2 -1 0 1 2 3 
 I am LYING DOWN / SITTING/ STANDING/ WALKING (Please circle your choice) 
 Since the last beep I’ve used: (Please tick) 
 Nothing □ 
 Alcohol □ Type (e.g bottle of beer, small glass of wine)...........………How many?…... 
 Cannabis□ Number of joints / bongs............……………………………………………… 
 
 Other drug 1 □ Name....................... How much?.............  
 Other drug 2 □ Name........................ How much?.............  
 Other drug 3 □ Name........................ How much?.............  
  It is now exactly……………hrs…………….minutes………… 
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APPENDIX H                                            BIS/BAS scale 
 
Name of Researcher:      
Name of Participant:             Date: 
 
Participant Number   
 
 
Each item of this questionnaire is a statement that a person may either agree with or disagree 
with.   
For each item, indicate how much you agree or disagree with what the item says.   
Please respond to all the items; do not leave any blank.  
Choose only one response to each statement.   
Please be as accurate and honest as you can be.  
Respond to each item as if it were the only item.  That is, don't worry about being "consistent" in 
your responses.  
Choose one from the following four response options: 
 
 Very true 
for me 
Somewhat 
true for me 
Somewhat 
false for me 
Very false 
for me 
 
1. A person's family is the most 
important thing in life. 
    
2.  Even if something bad is about to 
happen to me, I rarely experience 
fear or nervousness. 
    
3.  I go out of my way to get things I 
want. 
    
4.  When I'm doing well at something 
I love to keep at it. 
    
5.  I'm always willing to try something 
new if I think it will be fun. 
    
6.  How I dress is important to me.  
 
   
7.  When I get something I want, I 
feel excited and energized. 
    
8.  Criticism or scolding hurts me 
quite a bit. 
    
9.  When I want something I usually 
go all-out to get it. 
    
10.  I will often do things for no other 
reason than that they might be fun. 
    
11.  It's hard for me to find the time to 
do things such as get a haircut. 
    
12.  If I see a chance to get 
something I want I move on it right 
away. 
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13.  I feel pretty worried or upset when 
I think or know somebody is angry at 
me. 
    
14.  When I see an opportunity for 
something I like I get excited right 
away. 
    
15.  I often act on the spur of the 
moment. 
    
16.  If I think something unpleasant is 
going to happen I usually get pretty 
"worked up." 
    
17.  I often wonder why people act the 
way they do. 
    
18.  When good things happen to me, 
it affects me strongly. 
    
19.  I feel worried when I think I have 
done poorly at something important. 
    
20.  I crave excitement and new 
sensations. 
    
21.  When I go after something I use a 
"no holds barred" approach. 
    
22.  I have very few fears compared to 
my friends. 
    
23.  It would excite me to win a 
contest. 
 
 
   
24.  I worry about making mistakes.  
 
   
 
Carver, C. S., & White, T. L. (1994). Behavioral inhibition, behavioral activation, and affective 
responses to impending reward and punishment: The BIS/BAS scales. Journal of Personality and 
Social Psychology, 67, 319-333. 
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APPENDIX I 
FACTOR ANALYSES 
 
Mood scales 
A principle components analysis revealed two distinct mood scales 
      1  2 
Cheerful      .874 
Excited      .785 
Relaxed      .656 
Satisfied      .762 
Happy      .778 
Lonely        .569 
Anxious        .793 
Irritated        .626 
Sad        .853 
Guilty         .796          
% variance explained    32.9  31.2    
Cronbachs Alpha     α 0.85  α 0.82 
Mean score (S.D)     3.88 (1.30) 2.00 (1.26) 
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Bipolar symptom scales 
A principle component analysis revealed two separate scales, however ‘restless and fidgety’ 
(originally mania) loaded onto both factors (higher onto depression), therefore was excluded.  
     
       1  2 
I feel slowed down     .573  
I feel low      .880 
I feel bad about myself     .900 
I feel fearful      .839 
I am full of energy       .808 
I am full of good ideas       .837 
I am high        .785 
% variance explained     40.2  29.2 
Cronbachs Alpha      α 0.82  α 0.75 
Mean score (S.D)      2.10 (1.33) 2.71 (1.38) 
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APPENDIX J 
 
correlate pos neg man dep 
 
(obs=909) 
 
             |      pos      neg      man      dep 
-------------+------------------------------------ 
         pos |   1.0000 
         neg |  -0.4616   1.0000 
         man |   0.5809  -0.0359   1.0000 
         dep |  -0.3936   0.8180  -0.0649   1.0000 
 
 
 
 
 
